Published in final edited form as:

Biochim Biophys Acta. 2014 December ; 1846(2): 638–654. doi:10.1016/j.bbcan.2014.10.007.

mTOR signaling in tumorigenesis

Kai Xu^{a,b}, Pengda Liu^{b,*}, and Wenyi Wei^{b,*}

^aDepartment of Otolaryngology-Head and Neck Surgery, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, People's Republic of China, 430030

^bDepartment of Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215

Abstract

mTOR (the mechanistic target of rapamycin) is an atypical serine/threonine kinase involved in regulating major cellular functions including growth and proliferation. Deregulations of the mTOR signaling pathway is one of the most commonly observed pathological alterations in human cancers. To this end, oncogenic activation of the mTOR signaling pathway contributes to cancer cell growth, proliferation and survival, highlighting the potential for targeting the oncogenic mTOR pathway members as an effective anti-cancer strategy. In order to do so, a thorough understanding of the physiological roles of key mTOR signaling pathway components and upstream regulators would guide future targeted therapies. Thus, in this review, we summarize available genetic mouse models for mTORC1 and mTORC2 components, as well as characterized mTOR upstream regulators and downstream targets, and assign a potential oncogenic or tumor suppressive role for each evaluated molecule. Together, our work will not only facilitate the current understanding of mTOR biology and possible future research directions, but more importantly, provide a molecular basis for targeted therapies aiming at key oncogenic members along the mTOR signaling pathway.

Keywords

mTORC2; mTORC1; mTOR pathway; mouse model; tumorigenesis

© 2014 Elsevier B.V. All rights reserved.

*To whom correspondence should be addressed: Pengda Liu, Ph.D., Department of Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, Phone:(617)-735-2493, pliu1@bidmc.harvard.edu. Wenyi Wei, Ph.D., Department of Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, Phone: (617)-735-2495, wwei2@bidmc.harvard.edu.

Competing interests statement

The authors declare no competing interests.

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Introduction

Rapamycin is an immune-suppressant drug extracted from a bacterial strain isolated on the Easter Island [1]. In 1991, a genetic screen for rapamycin-resistant mutations in budding yeast *Saccharomyces cerevisiae* led to the discovery of both *TOR1* and *TOR2* genes [2], the yeast homologues of mammalian mTOR. Subsequent biochemical studies in mammalian cells further led to the identification of a ~290 kDa protein, which was termed mTOR (mechanistic target of rapamycin, also known as the mammalian target of rapamycin) [3–5]. mTOR is an atypical serine/threonine kinase that belongs to the PIKK (phosphoinositide 3-kinase related protein kinase) super-family, which includes multiple members of large-size kinase proteins that are involved in nutrient sensing (mTOR) and DNA repair [ATM (ataxia-telangiectasia mutated), ATR (ataxia-telangiectasia and Rad3-related) and DNAPK (DNA-dependent protein kinase)] [6].

In yeast, two *TOR* genes have been identified and termed as *TOR1* and *TOR2*, both of which participate in two separate protein complexes TORC1 and TORC2, respectively [7]. Notably, both TOR1 and TOR2 are found in the TORC1 complex that mainly regulates cell growth; whereas only TOR2 is found in the TORC2 complex, which is important for cell cycle-dependent polarization of the actin cytoskeleton [8]. On the other hand, in mammalian cells, there is only one *mTOR* gene identified thus far [3, 4]. Furthermore, as an evolutionarily conserved kinase, mTOR functions largely as the catalytic subunit of two distinct protein kinase complexes, designated as mTORC1 (mTOR complex 1) and mTORC2 (mTOR complex 2), respectively [9].

Both mTORC1 and mTORC2 complexes share common subunits including mTOR and mLST8 (mammalian lethal with sec-13 protein 8, also known as GβL) [10–12], whereas mTORC1 contains its unique subunit, Raptor (regulator-associated protein of mammalian target of rapamycin), and the specific components including Rictor (rapamycin-insensitive companion of mTOR) and mSin1 (mammalian stress-activated map kinase-interacting protein 1, also termed MAPKAP1) define mTORC2 [13–16] (Figure 1). Critically, both Raptor and Rictor serve as scaffolding proteins to regulate the assembly, localization and substrate binding of mTORC1 and mTORC2, respectively [17]. However, it appears that mLST8 is essential for the mTOR/Rictor, but not the mTOR/Raptor interaction, while the underlying molecular mechanism is not fully understood [18]. Sin1 is also considered as a scaffolding protein regulating the assembly and activity of mTORC2 [15, 19, 20], while the detailed complex organization remains largely elusive in part due to the lack of structural evidence for the mTORC2 holo-enzyme. Furthermore, other additional regulatory components have also been reported to be involved in mTOR complex function [17]. For example, DEPTOR (DEP domain containing mTOR-interacting protein) acts as an endogenous mTOR inhibitor that expresses at low levels in most cancers [21]. Unlike DEPTOR, which inhibits both mTORC1 and mTORC2, PRAS40 (proline-rich Akt substrate 40 kDa) binds the mTOR kinase domain in a phosphorylation-dependent manner and only suppresses the kinase activity of mTORC1 [22, 23]. On the other hand, Protor1/2 (protein observed with Rictor 1 and 2) binds Rictor, and is only present in mTORC2, to increase the mTORC2-mediated activation of SGK-1 (serum/glucocorticoid regulated kinase-1) [24, 25].

The mTOR signaling pathway is pivotal in regulating major cell functions including cell growth, proliferation and metabolism [17]. To this end, mTORC1 and mTORC2 have been shown to play critical yet functionally distinct roles in controlling different cellular processes. Specifically, mTORC1 largely regulates protein translation and cell metabolism through sensing intra-cellular as well as extra-cellular stimuli, such as stress, nutrients, energy, oxygen levels and growth factors [7, 17]. In addition, it also directly phosphorylates many downstream targets including 4E-BP1 (eukaryotic translation initiation factor 4E binding protein 1), S6K (S6 kinase), SREBP (sterol regulatory element-binding protein) and autophagy components to promote protein and lipid synthesis, lysosome biogenesis, energy metabolism and to inhibit autophagy [17]. On the other hand, mTORC2 is less sensitive to nutrients but largely responsive to extra-cellular growth factors [13, 14]. However, the exact molecular mechanism for how mTORC2 senses extra-cellular growth factor stimulation is still largely unclear, while the only available knowledge is that ribosome association of mTORC2 is critical for its activation [17]. Nonetheless, once mTORC2 is activated, it phosphorylates major downstream target proteins including AGC family of kinases, such as Akt, SGK and PKC (protein kinase C) [26] to further augment the kinase cascade to exert their cellular functions.

Consistent with a critical role in regulating cell growth and metabolism, deregulation of the mTOR signaling is commonly observed in human cancers [27–29]. To this end, mutations or loss-of-function of upstream regulator genes such as *TSC1/2* (tuberous sclerosis complex 1/2) or *LKB1* (liver kinase B1) have been closely linked to clinical tumor syndromes including the Tuberous Sclerosis complex and the Peutz-Jeghers syndrome, respectively [30, 31]. More importantly, hyper-activation of PI3K and Akt, or genetic loss or mutation of *PTEN* (phosphatase and tensin homologue), a negative suppressor of the PI3K signaling, have been observed in many types of human cancers [32]. Given that hyper-activation of the mTOR pathway in cancer contributes significantly to cancer initiation and development, targeting the oncogenic mTOR pathway components could potentially be an effective cancer treatment strategy [17]. In fact, FDA (Food and Drug Administration) has approved rapamycin and its analogs Temsirolimus and Everolimus for the treatments of certain types of tumors including renal cell carcinoma and mantle cell lymphoma [33]. However, considering rapamycin and its analogs have only reached modest efficacy in current clinical trials, an in-depth further understanding of the molecular mechanisms for the mTOR signaling pathway, as well as identifying new therapeutic targets along this signaling cascade may provide fruitful targets for cancer therapy [17, 34].

Thus in this review, we summarize the available genetic mouse models for both the mTORC1 and mTORC2 complexes. Furthermore, we also explore their upstream regulators or downstream targets to define a clear functional role for these critical molecules in their physiological settings as well as in tumorigenesis, which will provide insights for further speculations regarding whether they are potential drug targets for effective cancer treatment.

1. The roles of the mTOR signaling pathway components in tumorigenesis: revealed by mouse models

1.1 Shared components for the mTORC1 and mTORC2 complexes

1.1.1. mTOR—In an effort to elucidate the physiological function of mTOR, two groups independently generated the *mTOR*^{−/−} mice in 2006 and found that loss of *mTOR* leads to embryonic lethality at the E5.5–6.5 stage in part due to impaired cell proliferation and gastrulation [35, 36]. Whereas, *mTOR*^{+/-} mice develop normally and do not show any overt development defects [35, 36]. Interestingly, the *mTOR*^{H/H} (hypomorphic *mTOR*) mice, which are viable and only express 25% of total mTOR levels compared to wild-type mice, show an approximately 20% increase in lifespan, indicating that inhibiting mTOR may lead to a prolonged lifespan [37]. In order to identify the physiological function of mTOR in various tissues, an *mTOR* conditional KO (knockout) mouse model was generated to specifically ablate the *mTOR* gene in muscle (Figure 2). These mice display severe myopathy and premature death due to impaired oxidative metabolism and glycogen accumulation [38], further indicating a critical role for mTOR in regulating the development and metabolism processes.

1.1.2. mLST8 (GβL)—The *mLST8*^{−/−} mice die around E10.5 in part due to defects in vascular development [18]. Unexpectedly, although mLST8 participates in both mTORC1 and mTORC2 complexes, the *mLST8*^{−/−} mice showed deficiency largely in mTORC2, but not mTORC1, related functions [18]. Consistently, *mLST8*^{−/−} MEFs (mouse embryonic fibroblasts) showed impaired Akt and PKCα phosphorylation, with unaffected S6K phosphorylation [18]. Mechanistically, biochemical studies demonstrated that mLST8 is functionally required for the mTOR/Rictor interaction but not the mTOR/Raptor interaction, which supports the notion that *mLST8* genetic ablation only affects mTORC2 but not mTORC1 signaling [18]. However, additional in-depth studies are required to understand the underlying molecular mechanism for the different roles of mLST8 in governing the activation of mTORC1 versus mTORC2 kinase complex.

1.2 mTORC1 specific components

1.2.1 Raptor—*Raptor*^{−/−} mice are embryonic lethal and die at E5.5–6.5, due to blastocysts failure for expansion and differentiation [18]. Considering the essential role for Raptor in maintaining mTORC1 complex organization and function, several tissue-specific *Raptor* KO (knockout) mice also showed the phenotypes similar to a deficiency in mTORC1 function. Specifically, the adipose-specific *Raptor* KO mice have much less adipose tissue, and are less likely to get hyper-cholesterolemia and obesity, which emphasizes the critical role of Raptor and mTORC1 in adipose metabolism and whole body energy homeostasis [39] (Figure 2). Furthermore, the skeletal muscle-specific *Raptor* KO mice exhibit severe muscle dystrophy, with little or no fat underneath skin, eventually leading to premature death [40]. Similarly, heart-specific *Raptor* KO mice die from heart failure five weeks after tamoxifen-induced genetic ablation of Raptor, likely caused by the lack of adaptive cardiomyocyte growth, as well as increased apoptosis and autophagy in cardiac tissue [41]. Echoing the pivotal role of mTORC1 in development, the central nervous system specific

Raptor KO mice slow brain growth starting at E17.5 and die shortly after birth [42]. The only viable *Raptor* conditional KO mouse model are liver-specific *Raptor* KO mice, which exhibit 40% smaller liver mass, smaller hepatocyte and less protein content [43], arguing for a critical physiological role of mTORC1 in maintaining protein synthesis and cell growth.

Notably, a tamoxifen (TAM)-inducible conditional *Raptor* KO mouse model (*Raptor^{fl/fl}/CreER^{+TAM}*) was generated in 2012, where depletion of *Raptor* in adult mice with TAM in all tissues caused body weight loss and death within 17 days, with impairment of granulocyte and B cell development in bone marrow [44]. In order to investigate the critical role of *Raptor* in established acute myeloid leukemia (AML), *Raptor^{fl/fl}*, *Raptor^{+/-}/CreER* and *Raptor^{fl/fl}/CreER* AML mice were generated by transplantation of the *MLL-AF9* fusion gene modified hematopoietic progenitor cells from *Raptor^{fl/fl}*, *Raptor^{+/-}/CreER* and *Raptor^{fl/fl}/CreER* mice into lethally irradiated syngeneic recipients [44]. Notably, further analyses of these AML mouse models revealed that *Raptor* deletion remarkably impaired AML progression owing to an increased induction of cellular apoptosis [44]. Interestingly, although loss of *Raptor* significantly inhibited AML stem cells initiation, the self-renewal ability for these cells was not affected [44], indicating that mTORC1 activity is essential for AML propagation but not AML stem cell self-renewal.

1.3 mTORC2 specific components

1.3.1 Rictor—Similar to the phenotypes of *mLST8^{-/-}* mice, the *Rictor^{-/-}* mice exhibit vascular development defects and die around E10.5–11.5 [18, 45]. Thus, in order to examine the physiological role of *Rictor* *in vivo*, various tissue-specific KO mouse models were established in recent years. Specifically, the muscle-specific *Rictor* KO mice display impaired insulin-stimulated glucose uptake, elevated glycogen synthase activity and mild glucose intolerance, indicating an impairment of the glucose transportation process [46] (Figure 2). Similar to muscle-specific *Rictor* KO mice, the liver-specific *Rictor* KO mice and the fat-cell specific *Rictor* KO mice also show defects in glucose metabolism [47, 48]. Furthermore, compared to their wild-type littermates, neuron-specific *Rictor* KO mice exhibit a reduction in brain size, neuron cell size as well as whole-body size [49]. These mice also displayed a Schizophrenic-like behavior according to the results from an independent behavior study [50]. Interestingly, a recent study revealed that the lifespan of male, but not female mice, was significantly decreased in *Rictor^{+/-}*, liver-specific *Rictor^{-/-}* mice or *Rictor^{fl/fl}/Cre* mice, indicating the association of *Rictor* with aging in a gender-dependent manner [51]. However, the underlying molecular mechanism(s) driving this difference remains elusive and thus warrant further in-depth investigations.

Rictor has also been tightly linked with tumorigenesis according to results obtained from the Sabatini group [52]. By crossing the *Pten^{+/-}* mice with *mTOR^{+/-}*, *Rictor^{+/-}*, *Raptor^{+/-}* or *mLST8^{+/-}* mice, and monitoring the cancerous phenotypes of their off-springs, they found that both the *Pten^{+/-}/mTOR^{+/-}* and *Pten^{+/-}/mLST8^{+/-}* mice exhibit a longer lifespan than *Pten^{+/-}* counterparts. More importantly, compared with *Pten^{+/-}* mice that develop spontaneous cancers in multiply organs, the *Pten^{+/-}/Rictor^{+/-}* mice exhibit less prostate tumor incidences, less severe lesions and a longer lifespan [52]. Given the fact that *Rictor* is a haplo-insufficient gene, this study supports the notion that mTORC2 signaling is required

for the development of *Pten* heterozygous-induced prostate cancer [52]. Hence, developing specific inhibitors for mTORC2 may represent a potential novel therapeutic approach for the treatment of cancer patients, especially in the patient population with *Pten* loss.

1.3.2 Sin1 (MAPKAP1)—Functioning as another essential and unique mTORC2 subunit, the critical role of Sin1 in maintaining mTORC2 complex integrity and activity was first evaluated by three independent groups in 2006 [15, 16, 19]. The *Sin1*^{-/-} mice are embryonic lethal and die between E10.5~15.5, in part due to defects in embryonic cardiovascular development [53]. Furthermore, ablation of *Sin1* in B cells leads to an increase in V(D)J recombinase enzymatic activity and enhanced pro-B cell survival, resulting from elevated IL-7R and RAG1/2 gene expression [53] (Figure 2). Moreover, *Sin1* deficiency was found to result in an increase in the number of T-regulatory cells in the thymus. This deficiency, however, has no effect on the growth and proliferation of T cells [54], further supporting a critical role for Sin1 in regulating immune response through modulating both B and T cell respiratories. However, the physiological role of Sin1 in contributing to tumorigenesis remains unclear. Therefore, it will be important to develop additional *Sin1* tissue-specific KO or Transgenic (Tg) mice as well as various compound mouse models such as crossing *Sin1* conditional KO mice with *Pten*^{+/-} mice to fully understand the critical role of Sin1 in tumorigenesis.

1.4 mTORC1 upstream regulators

1.4.1. TSC1/2—The TSC complex is generally considered as a heterodimer formed by TSC1 (also named hamartin) and TSC2 (also termed as tuberin) [55]. Recent studies also revealed TBC1D7 (tre2-bub2-cdc16 1 domain family, member 7) as a third subunit of the TSC complex [56]. However, TBC1D7 gene mutations are not commonly observed in TSC patients [56], suggesting that it might not be an essential component. Under physiological stimulation triggered by amino acids, growth factors, stress, energy as well as oxygen, TSC2 is phosphorylated by various upstream kinases including Akt [57], ERK [58] or RSK [59], to release its inhibition as a GAP (GTPase-activating protein) for the Rheb (ras homolog enriched in brain) GTPase, and to convert Rheb to its active GTP-bound form for mTORC1 activation [17]. Meanwhile, Akt-mediated phosphorylation of TSC2 also results in the dissociation of the TSC complex from the lysosome and subsequent activation of mTORC1 [60]. On the other hand, AMPK (AMP-activated protein kinase) can phosphorylate TSC2, leading to its potent suppression of mTORC1 under energy deprivation conditions [61]. In addition to phosphorylation-mediated regulation of mTORC1 activation, a recent study from the Sabatini group, also revealed an amino acid-mediated and a Rag-dependent “inside-out” mTORC1 activation mechanism [62]. Specifically, changes in lysosomal amino acid levels may guide the Rag proteins to release the TSC1/2 complex from the lysosome, as well as to recruit mTORC1 to the lysosomal surface for activation [62, 63].

Notably, Tuberous Sclerosis is an autosomal dominant genetic disease defined by mutations of either *TSC1* or *TSC2*, and is characterized by the formation of hamartomas in the brain, skin, kidneys, lungs, eyes and heart [30]. Pathologically, loss of heterozygosity of either *TSC1* or *TSC2* gene has been found in many TSC patients and shown to be a driving-force

for the disease [64]. However, no particular hot-spot mutations of *TSC1* or *TSC2* have been identified [30], highlighting a possible tumor suppressor role for TSC1 or TSC2.

The phenotypes of *TSC1/2* KO mice are summarized in Table 2. Notably, multiple mouse models clearly support the notion that both TSC1 and TSC2 function as tumor suppressors. Specifically, *Tsc1*^{-/-} mice die around E10.5–11.5 due to failed closure of the neural tube, while 64% of *Tsc1*^{+/-} mice develop renal tumors and 71% of *Tsc1*^{+/-} mice develop liver hemangiomas by 15–18 months [65]. In addition, *Tsc2*^{-/-} mice die at E9.5–12.5 from hepatic hypoplasia, while *Tsc2*^{+/-} mice display a 100% incidence of multiple bilateral renal tumors, 50% incidence of liver hemangiomas and a 32% incidence of lung adenomas by 15 months [66]. Another independent study generated *Tsc1*^{+/-} mice in different genetic backgrounds and reported that 95% of *Tsc1*^{+/-} *C3H* mice develop macroscopically visible renal tumors, while 80% of *Tsc1*^{+/-} mice exhibit renal cell carcinomas at the age of 15–18 months [67]. Furthermore, extra-renal tumor lesions in liver, spleen and uterine were also observed in both *C3H* and *Balb/c* mice [67]. Taken together, these mouse models strongly support TSC2 and TSC1 as physiological tumor suppressors.

In order to circumvent the embryonic lethality issue for *Tsc1/2* homozygous mice, a series of conditional KO mouse models have been further developed. Specifically, prostate epithelium *Tsc1* KO mice develop prostatic intraepithelial neoplasia at the age of 6 months, and progress to carcinoma at the age of 16 to 22 months [68]. In another study, liver-specific *Tsc1* KO mice manifest spontaneous sporadic hepatocellular carcinoma accompanied with liver inflammation, necrosis and regeneration [69]. Considering that nutrient availability directly regulates TSC1 for mTORC1 activation, this model indicates that activation of mTORC1 might be the bridge between diet and cancer [69]. Furthermore, an inducible *Tsc1* deletion system has been recently introduced into mouse primary mammary tumor cells (*Tsc1*^{fl/fl}/*MMTV-PyMT*), which demonstrated that deletion of *Tsc1* significantly promoted breast cancer cell growth *in vivo* [70]. In addition, another group further generated and compared the cancerous phenotypes of *Tsc1*^{fl/fl}/*Pten*^{fl/fl}/*Alb*^{Cre} mice with *Tsc1*^{fl/fl}/*Alb*^{Cre} mice or *Pten*^{fl/fl}/*Alb*^{Cre} mice. Notably, the liver of *Tsc1*^{fl/fl}/*Pten*^{fl/fl}/*Alb*^{Cre} mice developed tumors more rapidly and to a greater degree than any other strains, indicating that loss of *Tsc1* and *Pten* may work synergistically in promoting tumorigenesis [71]. On the other hand, the tumor suppressor role of TSC2 is supported by the report that almost all uterine-specific *Tsc2*^{-/-} mice exhibit uterine leiomyomas at the age of 3 months and myometrial proliferation at the age of 6 months [72]. However, compared with the *Pten*^{+/-} mice, the *Pten*^{+/-}/*Tsc2*^{+/-} mice do not show any advantage in neither promoting prostate adenocarcinoma development nor facilitating tumor progression [73]. This suggests that TSC2 might exert its tumor suppressor function differentially from TSC1, warranting further investigation for the underlying molecular mechanism(s).

1.4.2. Rheb—After establishing TSC1/2 as the upstream negative regulator of mTORC1, studies to determine the molecular link between the TSC complex and the mTORC1 complex subsequently led to the identification of Rheb, a small GTPase [74–76]. Rheb is a member of the Ras superfamily of GTP-binding proteins, with two isoforms (Rheb1 and Rheb2), localized on the endomembrane system [17]. However, only lysosome membrane-associated Rheb has been demonstrated to possess mTORC1 activating capacity, where the

Rag-Ragulator complex shuttles the inactive mTORC1 to GTP-bound Rheb for its activation [17, 77]. Compared with Rag-Ragulator signaling, which is essential in sensing the intracellular amino acid levels through an “inside-out” mechanism [62], Rheb is mainly regulated by the TSC complex, which receives the systematic nutrient signals, such as growth factors, to trigger activation of the Akt pathway to subsequently phosphorylate TSC2, releasing it from the lysosomal membrane surface and its inhibition of Rheb [78].

Rheb KO mouse models have been established and mainly demonstrate the vital role of Rheb in developmental process. The *Rheb*^{-/-} mice die around mid-gestation due to defects in cardiovascular development [79]. The developmental impairments were also confirmed by both smaller body size and a decreased proliferation capacity of *Rheb*^{-/-} MEFs compared to wild type MEFs [79]. As to the isoform specific knockout mice, the *Rheb1*^{-/-} mice die between E10.5 and E11.5, whereas the *Rheb2*^{-/-} mice develop normally and show no obvious defects until adulthood, indicating that Rheb1, but not Rheb2, is essential for embryonic survival and mTORC1 signaling [80]. To further examine the physiological role of Rheb1 in various tissues, *Rheb1* neural progenitor cell conditional KO mice were generated and exhibit impairment of brain postnatal myelination, but no obvious defects in early postnatal brain development was observed, suggesting that Rheb1 plays a role in selective cellular adaptation [80]. Another study using liver-specific *Rheb* KO mice showed increased mitochondria content in liver, and further proved the mitochondrial localized Rheb promotes mitophagy, contributing to the maintenance of optimal mitochondrial energy production [81].

A series of mouse models and clinical evidences also support the notion that *Rheb* may act as an oncogene in various cancer settings. For example, after adoptive transferring an *Eμ-Myc* lymphoma mouse model, *Rheb* acted as an oncogene in promoting lymphoma progression as well as drug-resistance [82]. Furthermore, another independent study using a *Rheb* transgenic mouse model demonstrated that *Pten* haplo-insufficiency and *Rheb* overexpression worked synergistically to promote prostate cancer progression [83]. Moreover, systematic examination of the clinical database revealed a positive correlation between an increase in Rheb expression levels and a higher cancer occurrence rate in breast, liver, lung, head and neck, and bladder [84]. Cumulatively, these results indicate that Rheb acts as an oncogene and thus is a potential therapeutic target for certain types of cancer.

1.4.3. RAG—Similar to Rheb, the Rag family of proteins is also a subgroup of Ras GTPase, including four isoforms in mammals, RagA, RagB, RagC and RagD. Unlike other Ras family members, the Rag GTPases function by forming heterodimers consisting RagA or RagB with RagC or RagD [85]. As mentioned previously, the Rag-Ragulator complex is essential in sensing the intracellular amino acids levels to facilitate the subsequent activation of mTOR1 [86, 87]. Considering GTP-bound RagA/B alone can activate the mTORC1 kinase even in the absence of amino acids, the loading of RagA/B with GTP appears to be functionally predominant over GTP or GDP-loaded RagC/D [86, 87], which also explains why recent genetic mouse models are largely focused on manipulating RagA and RagB.

In order to illustrate the physiological role of RagA, a knock-in mouse model that expresses a constitutive active form of *RagA* (Q66L) has been generated, which exhibited defects in

glucose homeostasis and autophagy and die on postnatal day 1 [88]. Furthermore, the *RagA*^{-/-} mice show a loss of mTORC1 activity, profound developmental defects and die around E10.5, whereas the *RagB*^{-/-} mice show no overt developmental abnormality and no obvious reduction in mTORC1 activity, indicating that RagA, but not RagB, is more important for mTORC1 activity [89]. Given that whole body and liver specific *RagA*^{-/-}/*RagB*^{-/-} mice exhibit a more robust loss of mTORC1 activity, the phenotype difference between *RagA*^{-/-} and *mTOR*^{-/-} (or *Raptor*^{-/-}) mice may be in part due to the compensation effect of RagB [89]. Interestingly, the heart-specific *RagA*^{-/-}/*RagB*^{-/-} mice do not show an impairment of mTORC1 activity, but manifest cardiac hypertrophy, defective autophagy and lysosome function, whereas none of the heart-specific *RagA*^{-/-} or *RagB*^{-/-} mice shows cardiac hypertrophy [90]. Thus, different phenotypes of various tissue-specific *Rag* KO mice indicate that the role of Rag GTPase in governing mTORC1 activation may be tissue-specific or context-dependent.

Thus far, no *Rag* genetic mouse model has been associated with tumor formation yet. However, several GAPs (GTPase-activation proteins) have been linked to tumorigenesis. Specifically, the tumor suppressor gene *Flcn* (*folliculin*), the mutation of which is considered the driving force behind the pathologic phenotypes of the BHD (Birt-Hogg-Dubé) syndrome, is necessary for mTORC1 activation in part by acting as a GAP for RagC/D [91]. Moreover, it has also been demonstrated that the protein complex GATOR could serve as the GAP for RagA/B, and inactivation mutations of GATOR1 components including DEPDC5 and NPRL2 have been associated with aberrant mTORC1 activation in cancer cell lines [92]. However, the physiological contributions of these two proteins to tumorigenesis *in vivo* still require additional studies by utilizing *Gator1* or *Flcn* KO mice.

1.4.4. AMPK—AMPK is a conserved serine/threonine kinase, functioning as a fuel sensor to maintain cellular energy homeostasis [93, 94]. Once activated under low energy state, AMPK inhibits the anabolic processes such as protein and lipid biosynthesis, and promotes catabolic pathways including fatty acid oxidation and glycolysis, resulting in the fostered generation of ATP. AMPK exists as a hetero-trimetric complex consisting of a catalytic subunit α and two regulatory β and γ subunits [93]. Two or three isoforms of each subunit have been identified in mammals (namely $\alpha 1$, $\alpha 2$, $\beta 1$, $\beta 2$, $\gamma 1$, $\gamma 2$ and $\gamma 3$) [95]. It has been established that AMPK could negatively regulates the activation of mTORC1 complex indirectly in part through phosphorylation of the mTORC1 upstream regulator TSC2 to keep its suppression on Rheb [61] or directly via phosphorylation of the mTORC1 regulatory but essential component, Raptor, to trigger its interaction with 14-3-3 and subsequent dissociation from mTOR [96].

Given that AMPK acts as a key regulator of cellular metabolism, *Ampk* KO mouse models have been generated to closely examine the physiological roles of AMPK subunits on metabolism. Complete loss of AMPK kinase activity is not tolerated at the whole-body level *in vivo*, which has been supported by the observation that the *Ampka1*^{-/-}/*Ampka2*^{-/-} mice are embryonic lethal at E10.5 [97]. However, muscle-specific *Ampka1*^{-/-}/*Ampka2*^{-/-} mice are viable, but the skeletal muscle of these KO mice have an increased mass with larger myofibers compared to their wild type littermates [98], indicating a physiological role of AMPK activity in governing muscle function. On the other hand, loss of either isoform of

the AMPK catalytic $\alpha 1$ or $\alpha 2$ subunits is permissible, as the *Ampk $\alpha 1$ ^{-/-}* mice are largely normal, and the *Ampk $\alpha 2$ ^{-/-}* mice are viable but exhibit higher glucose levels in the feeding period and therefore are more likely to develop obesity under a high-fat diet [99]. Thus AMPK $\alpha 1$ and AMPK $\alpha 2$ may play non-redundant roles *in vivo*. This notion was further supported by the observation that bone tissue-specific *Ampk $\alpha 1$ ^{-/-}* mice showed elevated rate of bone remodeling, while the *Ampk $\alpha 2$ ^{-/-}* mice only show bone absorption phenotypes [100].

Notably, deletion of various AMPK regulatory subunits appears to have no significant effects on mouse survival. Specifically, the *Ampk $\gamma 3$ ^{-/-}* mice show impaired glycogen re-syntheses after exercise [101]. Furthermore, muscle-specific *Ampk $\beta 1$ /Ampk $\beta 2$* DKO mice are physically inactive and display reduced mitochondrial content in muscle cells [102], impinging a possible role of AMPK β in regulating energy homeostasis in muscle. More importantly, these findings paved the way for the clinical application of metformin, an AMPK-activating drug, in treating type 2 diabetes by increasing glucose uptake and fatty acid oxidation in skeletal muscles [103]. Interestingly, follow-up studies indicated that metformin may also reduce the incidence of cancer, especially colon and liver cancers in diabetic patients, implying a possible tumor suppressor role of AMPK [104].

In line with these findings, as a downstream effector of the tumor suppressor LKB1, AMPK is commonly characterized as a metabolic tumor suppressor. This was supported by a study demonstrating that ablation of the *Ampk $\alpha 1$* subunit, the only subunit in B cells, resulted in accelerated B-cell lymphomagenesis in an *Eu-Myc* transgenic mouse model [105]. Furthermore, loss of AMPK α signaling led to an enhancement of Warburg effects and increased HIF-1 α expression levels, which subsequently promoted glycolytic pathways and lymphoma progression [105]. Additionally, *Ampk $\alpha 2$ ^{-/-}*, but not *Ampk $\alpha 1$ ^{-/-}* MEFs exhibited increased susceptibility to *H-RasV12* transformation *in vivo* and tumorigenesis *in vitro* [106], indicating that AMPK $\alpha 1$ and AMPK $\alpha 2$ subunits may exert their tumor suppressor function in a tissue-dependent or context-dependent manner. On the other hand, another study revealed that AMPK activation during energy stress maintained the cellular NADPH levels and facilitated cell survival and tumor growth through redox regulation [107], revealing an oncogenic potential for AMPK in cells. Cumulatively, these results indicate that AMPK may in large act as a tumor suppressor in pre-tumor lesions. However, once the tumor is established, AMPK may promote tumor cell survival under metabolic stress [93], which warrants further detailed investigations with additional mouse modeling studies for clarification.

1.5 mTORC1 downstream substrates in tumorigenesis

The major function of mTORC1 is to control protein synthesis through directly phosphorylating translational regulators 4E-BP1 and S6K1 (S6 kinase 1) [120, 121]. Notably, recent work from the Manning group suggests that mTORC1 also regulates the protein turnover rate to balance protein synthesis and degradation largely through promoting NRF1-dependent elevation of proteasome levels [122]. Nevertheless, in both processes, mTORC1 activity is required for targeting a subset of its substrates for phosphorylation-mediated regulation to exert its biological functions.

1.5.1. 4E-BP1—mTORC1-mediated phosphorylation of 4E-BP1 prevents its binding with the cap-binding protein eIF4E, resulting in the initiation of cap-dependent translation [123]. Consequently, eIF4E-dependent translation enhances cell growth and proliferation by increasing translation of a subset of pro-oncogenic proteins involved in regulating cell survival, cell-cycle progression and angiogenesis, such as c-Myc, ornithine decarboxylase (ODC), cyclin D1, fibroblast growth factor (FGF) and vascular endothelial growth factor (VEGF) [17, 124].

To further understand the physiological role of 4E-BP1 *in vivo*, *4E-bp1*^{-/-} mice were generated in 2001, which led to markedly smaller white fat pads than wild-type animals, and the male KO mice showed an elevated metabolic rate. Furthermore, white adipose tissues derived from male KO mice showed manifestation and biomarkers of brown fat [125]. Additionally, *4E-bp1*^{-/-}/*4E-bp2*^{-/-} mice demonstrate an increased insulin resistance, coupled with increased S6K activity and impaired Akt activity in muscle, liver, and adipose tissue [126]. Together, these results clearly showed a protective role for 4E-BPs in the development of obesity. Moreover, *4E-bp1*^{-/-} mice also have an increased immature granulocytic precursor number and a decreased mature granulocytic number in bone marrow and spleen, indicating an important role for 4E-BP1 in early granulo-monocytic differentiation [127].

Moreover, consistent with an oncogenic role for eIF4E *in vivo*, a lymphoma mouse model that was reconstituted with *Eμ-Myc* HSCs (hematopoietic stem cells) transduced with *eif-4e* expression displays a disseminated pathology and is highly resistant to chemotherapy [9, 128]. Furthermore, more compound *4E-bp1* genetic mouse models indicate the function loss of 4E-BP1 might contribute to the growth of sporadic cancers. For example, compared with *p53*^{-/-} mice, *4E-bp1*^{-/-}/*4E-bp2*^{-/-}/*p53*^{-/-} mice manifest with an increased tumor-free survival, indicating that inactivation of 4E-BPs worked synergistically with p53 loss to promote cell proliferation and tumorigenesis [129]. Furthermore, another group showed that inactivation of 4E-BP1 through phosphorylation was a key effector in the oncogenic activation of the Akt and ERK signaling pathways [130]. Specifically, a phosphorylation-deficient mutant of 4E-BP1 that mimics a constitutively active form of 4E-BP1, showed impaired tumor growth *in vivo* [130]. Hence, these studies indicate the emerging role of 4E-BP1 as a tumor suppressor and might be a potential therapeutic target for the cancer patients bearing p53 loss or hyper-activation of Akt or ERK signaling.

1.5.2. S6K—Mammalian cells contain two isoforms of S6K, namely S6K1 and S6K2, both of which can be directly phosphorylated by mTORC1 [131, 132]. In 1998, the *S6k1*^{-/-} mice were generated and 20% smaller body mass and organ size were observed compared to their wild type littermates [133]. It was also reported that the viability of *S6k1*^{-/-}/*S6k2*^{-/-} mice were sharply reduced due to perinatal lethality [134]. Other than the growth deficiency phenotypes, glucose metabolism was dysfunctional in *S6k1*^{-/-} mice, whereas *S6k1*^{-/-} mice suffer from hypo-insulinaemia and are glucose intolerant due to reduced β-cell size in pancreas [135]. Therefore, the mice are less likely to develop obesity due to an increased lipolysis and metabolism rate, which is related to enhanced β-oxidation process [136, 137]. However, no cancer-related S6K mouse models have been established so far, which

warrants further investigation of whether S6K plays distinct roles in facilitating tumor formation in different tissues.

Mechanistically, a feedback loop has been established to indicate that S6K1 negatively regulates the stability of insulin receptor substrate 1 (IRS1) through directly phosphorylating the S307 and S636/S639 residues under nutrient deprivation conditions [136], as well as shuts down insulin or IGF-1 (insulin-like growth factor) mediated activation of Akt by phosphorylating Grb10 (growth factor receptor-bound protein 10) [138, 139]. Similarly, our group recently demonstrated that S6K1 could directly phosphorylates the essential component of mTORC2, Sin1, on both T86 and T398 residues to dissociate Sin1 from the functional mTORC2 complex to terminate its activity towards activating the Akt oncogenic signaling [20]. These results indicate that S6K might exert its oncogenic function through its positive regulation on protein synthesis, and could also display certain “tumor suppressor” role in inactivating growth factor signaling and lead to insulin resistant phenotype. Therefore, it will be important to develop additional genetically engineered mouse models within various tumor backgrounds to fully understand the physiological role of S6K in tumorigenesis.

1.5.3. SREBP—In addition to protein synthesis, mTORC1 also controls lipid synthesis, which is important for cell membrane homeostasis and cell survival [17]. SREBPs are responsive elements to sterols and are inactive when they are oriented to membranes of ER (endoplasmic reticulum) [140]. Under insulin or sterol depletion, SREBPs are truncated through a proteolytic cleavage process, thereby releasing their active forms from membranes and migrate into nucleus to activate relevant genes for lipid synthesis [140]. It has been reported that the activation status of mTORC1 positively correlates with SREBP1 activity [141, 142]. Mechanistically, mTORC1 regulates SREBP activity through several mechanisms, including S6K1-dependent and lipin-dependent regulations [142, 143]. However, whether and how mTORC1 may directly regulate SREBP activity is still largely unknown [17].

In mammalian cells, three SREBP isoforms (SREBP-1a, SREBP-1c, and SREBP-2) have been identified [144]. To demonstrate the function of individual SREBP isoforms, a series of SREBP isoform-specific KO mouse models have been developed (Table 3). Specifically, 55%–90% of *Srebp-1a*^{-/-}/*Srebp-1c*^{-/-} mice die on E11. Survived mice are normal at birth, but reduced synthesis of fatty acid and compensatory elevated expression of *Srebp-2* was observed throughout their lives [145]. Similarly, *Srebp-2*^{-/-} embryos die around E7–8 [145]. Different from the observed embryonic lethality of *Srebp-1*^{-/-} and *Srebp-2*^{-/-} mice, the *Srebp-1c*^{-/-} mice are viable, although a reduction in fatty acid and triglyceride synthesis is observed in liver [140, 146]. Consistent with the important role of SREBP in lipid synthesis, the liver-specific Tg *Srebp* mice display lipid metabolism disorders (Table 3) [145, 147, 148].

Given that increased *de novo* lipid synthesis is a hallmark of cancer pathogenesis, as well as elevated expression of SREBP target genes such as FAS (fatty acid synthase) is nearly ubiquitously observed in cancer cells [149], the SREBP pathway may possess a oncogenic property [142]. Consistent with this possibility, it has been reported that depletion of an

oncogenic mutant of the tumor suppressor p53 is sufficient to revert the breast cancer cell phenotype towards normal epithelia phenotype, which correlates with sterol synthesis at least partially through SREBP [150]. These findings further support the notion that the SREBP pathway is likely to be a potential drug target for anti-cancer therapies.

1.5.4. Autophagy Components—Autophagy was firstly discovered more than 40 years ago, when autophagic vacuoles (the smooth endoplasmic reticulum) were observed in the hepatocytes after cessation of phenobarbital induction, indicating that cells can digest cellular organelles [151]. Under nutrient deprivation conditions, mTORC1 is inhibited by AMPK and amino acid signaling [152], causing bulk cytoplasm and organelles to form double membrane sequestering vesicles or “autophagosomes”, which are then delivered to the lysosome for degradation [153]. mTORC1 has been shown to play a negative regulatory role in the autophagy process in mammals through several mechanisms. First, under rich nutrient conditions, mTORC1 directly phosphorylates ULK1 (uncoordinated 51-like kinase 1) and Atg13 (mammalian autophagy-related gene 13), leading to dissociation of the ULK1/Atg13/FIP200 (FAK family-interacting protein complex of 200 kDa) complex to inhibit autophagy. Second, mTORC1-dependent phosphorylation and inactivation of DAP1 (death-associated protein 1) acts as a braking system for the autophagic flux [154]. Third, phosphorylation of TFEB (transcription factor EB) by mTORC1 retains TFEB in the cytosol, which inhibits the transcription of critical autophagy related genes [155].

Several mouse models have been developed in order to reveal the physiological roles for individual autophagic genes. To this end, it has been reported that the *Tfeb*^{-/-} mice die between E9.5–10.5 due to severe defects in placental vascularization [156]. *Tfeb* osteoclasts-specific conditional KO mice show a decreased lysosomal gene expression and an increased bone mass. Moreover, though with defects in reticulocyte maturation, *Ulk1*^{-/-} mice are viable and show no overt developmental defects [157]. Thus it seems that different autophagic genes might play differential roles in the developmental process.

However, it is more important to understand the relationship between autophagy and cancer. To this end, autophagy has been considered to protect cells from cancer through removing damaged mitochondria, reactive oxygen species (ROS) and long-lived proteins [158]. Consistently, loss-of-function mutations of Beclin 1, an essential component of autophagy, have been found in several solid tumors [153]. More importantly, *Beclin1*^{+/-} mice exhibit higher rates of spontaneous malignancy [158], suggesting that Beclin 1 may play a tumor suppressor role *in vivo*. On the other hand, inhibiting autophagy enhanced the chemotherapeutic effects in part by promoting apoptosis in a lymphoma mouse model [159], arguing for an oncogenic role for the autophagy process. Thus, autophagy may be important to prevent cancer initiation but necessary for cancer cells to survive in energy and nutrient deficient conditions [17].

1.6 mTORC2 substrates in tumorigenesis

1.6.1. Akt—The serine/threonine kinase Akt, also known as protein kinase B, is one of the most commonly activated onco-proteins in human cancers [32, 162]. Notably, cancerous hyper-activated Akt accelerates cell growth and proliferation, facilitates resistance to

apoptosis as well as promotes angiogenesis [162, 163]. Three highly homologous Akt isoforms have been identified in mammals, namely Akt1 (also known as PKB α), Akt2 (PKB β) and Akt3 (PKB γ) [164]. Akt1 and Akt2 are ubiquitously expressed, while Akt3 is primarily expressed in the brain and testis [165]. Upon extra-cellular growth factors stimulation, activation of PI3K (phosphoinositide 3-kinase) leads to increased levels of PIP₃ (phosphatidylinositol-3,4,5-triphosphate), which serves as a lipid second messenger to recruit Akt, through its PH (pleckstrin homology) domain to the plasma membrane, as well as its activating kinase, PDK1 (phosphoinositide-dependent kinase 1) [166]. The Akt-PH/PIP₃ interaction induces a conformational change in Akt, which enables the exposure and phosphorylation of two critical residues, Thr308 and Ser473 [167], by PDK1 [168] and mTORC2 [169], respectively, achieving Akt full activation. Activated Akt will then phosphorylate a large spectrum of proteins in the cytoplasm, mitochondria and nucleus to exert its various physiological functions [170]. More than 200 Akt substrates have been identified so far and they all share a similar Akt recognizable consensus motif (RxRxxpS/pT) [171]. Interestingly, we recently observed that Akt activation is cell cycle-dependent. Furthermore, we identified that in addition to mTOR, Cdk2/Cyclin A directly phosphorylates Akt1 at its extreme C-terminus on S477 and T479 residues, which either primes for, or compensates for Akt-S473 phosphorylation, revealing a new regulatory mechanism for Akt activation [172].

Different cellular distributions and functions for three Akt isoforms have emerged after generation of the *Akt* isoform-specific KO mice by two independent labs [173–175]. Specifically, *Akt1*^{-/-} mice are smaller than their wild type counterparts and *Akt1*^{-/-} MEFs are more vulnerable to induced apoptosis [176], supporting a role for the Akt1 isoform in controlling body size and cell survival. On the other hand, *Akt2*^{-/-} mice develop an insulin resistance phenotype largely due to changes of hormones in liver and skeletal muscle, which reveals a critical role for Akt2 in maintaining glucose homeostasis [174, 177]. Consistent with a predominant expression pattern of Akt3 in the brain, the brain size and weight from *Akt3*^{-/-} mice are reduced by 25%, compared with their wild type counterparts [178, 179]. Although loss of a single Akt1 isoform is tolerated *in vivo*, combined deletion of additional Akt isoform(s) with Akt1 displays an embryonic lethality phenotype. Specifically, the *Akt1*^{-/-}/*Akt2*^{-/-} mice die shortly after birth, and are much smaller with impaired development of skin, skeletal muscle and bone [180]. Similarly, the *Akt1*^{-/-}/*Akt3*^{-/-} mice die between E11–12 due to severe defects in development of cardiovascular and nervous systems [179]. On the other hand, the *Akt2*^{-/-}/*Akt3*^{-/-} mice are viable but smaller, and exhibit severe glucose and insulin intolerance [181]. These results reinforce the notion that Akt1 is the major isoform for maintaining Akt function during the development.

Aberrant activation of Akt isoforms has been frequently observed in different organ-originated cancer patients [170]. This might be due to *Akt* gene amplification and/or *Akt* somatic mutations, which contribute to the pathological Akt hyper-activation. For example, the *Akt1-E17K* somatic mutation in the Akt PH domain occurring in human breast, ovarian and colorectal cancer patients is tightly associated with Akt hyper-activation, which could induce B-cell leukemia in a *Eμ-Myc* transgenic mouse model, while wild type Akt failed to do so [182]. Moreover, hyper-activation of the mTOR/Akt signaling might also stem from

mutations of signaling components upstream of Akt, which are also commonly observed in a series of human cancers, including somatic mutations of *PI3KCA* and loss-of-function mutations of *Pten* [183–187]. In addition, gene rearrangements leading to an in-frame fusion gene of *Akt3* with *Magi3* (membrane-associated guanylate kinase, WW and PDZ domain containing 3) has been found in breast cancer patients (8/235) [188], which produced a MAGI3–Akt3 fusion protein, resulting in the loss of the PH-domain-mediated suppression of Akt and subsequently constitutive activation of Akt3 [188].

To further determine the role of Akt isoforms in cancer, mouse models have been generated with an Akt isoform combined with various cancerous mouse models. Furthermore, application of a *polyoma middle T* (*PyMT*) and *ErbB2/Neu*-driven mammary adenocarcinomas model in the *Akt1*^{−/−}, *Akt2*^{−/−} and *Akt3*^{−/−} mice make it feasible to demonstrate the specific role of each Akt isoform in driving tumorigenesis under these unique conditions. Notably, in contrary to *Akt2*^{−/−} mice, the *Akt1*^{−/−} mice showed an inhibited tumor initiation with an accelerated tumor invasion [189]. Consistently, transgenic expression of *Akt1* or *Akt2* isoforms in transformed mammary glands also demonstrated that expression of *Akt1* accelerated tumor development and inhibited invasion, while expression of *Akt2* exhibited the opposite effects [190]. Hence, these results indicate that different Akt isoforms may exert unique roles in tumorigenesis in a context-dependent manner.

The mammalian PKCs comprise conventional PKCs (PKC-α, PKC-β and PKC-γ), novel PKCs (PKC-δ, PKC-ε, PKC-η and PKC-θ) and atypical PKCs (PKC-ζ and PKC-λ/ι) [191]. As a member of the AGC kinase family, activation of all PKC isoforms is also phosphorylation-dependent [26]. Activation of PKC not only requires hydrophobic motif phosphorylation by mTORC2 and kinase motif phosphorylation by PDK1, but also needs further stimulatory regulation by second messengers [26], which differs from the activation of Akt. Specifically, the second messengers for conventional PKCs is calcium and diacylglycerol; for novel PKCs is diacylglycerol but not calcium, while neither is required for the activation of atypical PKCs [192]. Most PKC isoforms are ubiquitously expressed in all tissues, although they may exert different roles under both physiological and pathological conditions [193].

To determine the exact physiological function of each PKC isoform, different PKC isoform KO mouse models were established and different phenotypes were observed (Table 4), indicating the essential role of PKC in the development of the immune system and central nervous system [194–203]. In addition, various transgenic mouse models further support the notion that different PKC isoforms may exert different roles in tumorigenesis. For example, PKC-ε and PKC-λ/ι are generally considered to be oncogenes. Pathologically, clinical studies further revealed the incidence and malignancy of malignant glioma are tightly correlated with PKC-ε activation [204]. Moreover, PKC-λ/ι has also been reported to promote Ras-mediated transformation and colon tumorigenesis in transgenic mice [205], and its oncogenic role was echoed by observed overexpression or hyper-activation in human non-small cell lung cancer [206] and ovarian cancer [207]. Furthermore, the PKC-β isoform is linked to carcinogenesis as *PKC-β*^{−/−} mice are resistant to azoxymethane (AOM)-induced colon carcinogenesis, while transgenic expression of PKC-β in *PKC-β*^{−/−} mice restored colon cancer development [208]. Moreover, another study revealed that PKC-β was essential

in VEGF-induced vasculogenesis [209]. Consistent with an oncogenic role for PKC kinases in tumorigenesis, several PKC inhibitors have been tested in clinical trials for treatment of cancer patients [210]. On the other hand, it is difficult to simply define the other PKC isoforms as either oncogene or tumor suppressor. For example, PKC- α transgenic mice illustrate a positive role for PKC- α in promoting cell proliferation [211]. However, clinical evidences suggest that over-expression of PKC- α in prostate, endometrial and hepatocellular cancers, whereas the down-regulation of PKC- α was observed in basal cell carcinoma and colon cancers, indicating that the role for PKC- α in tumorigenesis may be context-dependent [212]. To further evaluate the specific role of PKC isoforms in cancer, more PKC isoform-specific and tissue-specific knockout mouse models are warranted for further in-depth investigations in the near future.

1.6.3. SGK—As a member of the AGC kinase family, SGK1 is a serine/threonine kinase that under transcriptional control of various stimuli including serum, glucocorticoids, cytokines and other growth factors [213]. In addition to SGK1, two other isoforms have also been identified, namely SGK2 and SGK3 [214]. Similar to other members of the AGC kinase family such as Akt and PKC, activation of SGK requires phosphorylation by PDK1 and mTORC2 [215].

To evaluate the physiological roles of SGK isoforms *in vivo*, *Sgk1*^{-/-} mice were developed in 2002, and these mice show impaired renal sodium retention under low salt diet, due to decreased renal epithelial Na⁺ channel activity, which subsequently leads to lower blood pressure and glomerular filtration rate [216]. Moreover, *Sgk3*^{-/-} mice exhibit a delayed hair growth phenotype without a sodium chloride excretion abnormality [217]. Notably, *Sgk1*^{-/-}/*Sgk3*^{-/-} mice exhibit both phenotypes of *Sgk1*^{-/-} and *Sgk3*^{-/-} mice [217], suggesting that SGK1 and SGK3 possess non-redundant developmental functions *in vivo*. Although genetic ablation of SGK does not result in tumorigenesis, after induction by chemical carcinogen, *Sgk1*^{-/-} mice develop much less colonic tumors than their wild-type littermates, supporting a physiological role for SGK1 deficiency in counteracting carcinogenesis [213]. Consistently, the *Apc*^{Min/+}/*Sgk1*^{-/-} compound mice, generated by crossing *Sgk1*^{-/-} mice with an APC (adenomatous polyposis coli) tumor suppressor defective (*Apc*^{Min/+}) mice, develop much less intestinal tumors than *Apc*^{Min/+}/*Sgk1*^{+/+} mice, as well as associate with decreased levels of colonic β -catenin protein [218], further supporting an oncogenic role for SGK1 *in vivo*. Consistently, administration of SGK inhibitors promoted radiation-induced tumor cell apoptosis *in vitro* and decreased the number of tumors *in vivo*, supporting the notion that SGK facilitates colon cancer progression [219].

Mutations of SGK appear to be mutually exclusive with Akt mutations in cancer [220]. Both SGK and Akt share common downstream substrates, as well as are able to promote cell growth, proliferation and migration [220]. Accordingly, SGK3 has been observed to be able to compensate for Akt to facilitate tumorigenesis in many *PIK3CA* mutated cancer cells and breast tumors. Moreover, SGK3-dependent PDK1 signaling was shown to be required for tumor growth, indicating the oncogenic role of SGK3 [221]. Clinically, up-regulation of SGK1 has been reported in multiple tumor types, such as prostate cancer [222] and non-small cell lung cancer [223]. However, this phenotype is tissue-dependent, as decreased SGK1 expression was also found in adenomatous polyposis coli [218], adenomatous ovarian

cancer [224] and hepatocellular cancer [225]. Given that SGK is not essential in tumor cell survival, the physiological role of SGK in tumorigenesis may be tissue-dependent and context-dependent, which warrants further in-depth investigations in part by generating additional tissue-specific SGK transgenic mouse models.

Discussion

Hyper-activation of the PI3K/mTOR/Akt signaling pathway is among the most commonly observed pathological alterations in human cancers [32]. Since the identification of the yeast *TOR* gene in 1990s, the mTOR/Akt pathway has been considered a central regulator in controlling cell growth, proliferation and survival, as well as a promising anti-cancer drug target [229, 230]. In this review, we summarized the growing list of available genetic mouse models, pathological alteration status as well as downstream targets for key pathway components that are closely related to mTORC1 and mTORC2 (Table 1–4). More importantly, based on these physiological and pathological evidences, we assigned a possible role for each listed member for its role in tumorigenesis. Due to space limitation, we cannot include mouse models of some indirect regulators of mTOR complexes, such as PI3K [231, 232], PTEN [233, 234], PLD (phospholipase D) [235–237], LKB1 [238], FLCN [91, 239] and REDD1 (regulated in development and DNA damage responses 1) [240] in the current review, although they are also critical for our further understanding of how dysregulation of the mTOR signaling pathway facilitates tumorigenesis.

Extensive studies have greatly facilitated our current understanding of the biological functions of the mTOR pathway. However, clinical applications of inhibitors targeting key oncogenic members of this pathway, including mTOR, Akt, PKC, SGK and S6K, haven't achieved satisfactory clinical outcomes due to many reasons [33, 34, 210, 241]. Since rapamycin opens the mTOR research field, its application on treating mTOR-related diseases has been extensively studied. For example, rapamycin was the first drug examined to be able to extend the lifespan in mice [242]. However, comprehensive and large-scale assessment showed these effects were not due to ageing [243]. As rapamycin is a potent acute inhibitor for mTORC1 [3, 4] and chronic inhibitor for mTORC2 [244, 245], it has been used to combat various human cancers but only reached limited success [34]. For example, rapamycin analogs everolimus improved the progression-free survival in a clinical phase III study on patients with metastatic renal cell carcinoma that progressed on VEGFR-targeted therapy, but the objective response rate was only 1% [246]. More importantly, cancer patients received rapamycin typically developed an insulin resistance after prolonged treatments [247]. In addition to rapamycin, an allosteric mTOR inhibitor, some ATP-competitive mTOR kinase inhibitors are in clinical trials to treat cancer patients, including INK128 [248], AZD8055 [249] and AZD2014 [250]. Unfortunately, these compounds demonstrated only limited success in shrinking KRAS driven tumors [251], suggesting that targeting both mTORC1 and mTORC2 for inhibition might not be an optimal treatment option. Instead, mTORC2-specific inhibitors might shed new lights on targeted therapeutic avenues to treat cancer patients with deregulated mTOR signaling.

To this end, more thorough and in-depth understanding of how the mTOR/Akt pathway is regulated in normal cells and dysregulated in cancer cells would benefit the identification of

new mTORC2 upstream regulators, and more importantly might lead to the discovery of more potential anti-cancer drug targets. Achieving this goal will rely on thorough biochemical studies to examine the cellular functions, utilization of deep sequencing technology for analyzing the genetic alteration status of target genes in cancer patient samples, and more importantly, the establishment of additional sophisticated and comprehensive mouse models to examine the physiological role for each signaling component of mTOR, as well as to recapitulate human cancers in mice to facilitate the drug screening and clinical trials in the future. As the whole body knockout of *mTOR*, *mLST8* or *Sin1* core subunits leads to embryonic lethality, to appreciate the exact role of these critical mTOR modulators *in vivo*, tissue-specific knockout or transgenic mouse models are urged to be generated. In addition, only limited mouse models are currently available, preventing the fully understanding of the physiological contribution of many members along this signaling pathway to cancer and other human pathological conditions. Thus establishing mouse models for all critical mTOR pathway components including its core complex components, upstream regulators and downstream targets, will greatly help to pinpoint their critical roles in various cellular processes leading to tumorigenesis. Notably, the recently developed CRISPR technique has provided an efficient and accurate method to generate engineered mice with cancer patient-derived hotspot mutations [252], which may not only bypass the embryonic lethality issue caused by gene ablation, but also evaluate how significant a certain cancer patient hot mutation contributes to tumorigenesis in a mouse model and might facilitate the test of various treatments specifically targeting this mutation. For example, we recently identified a oncogenic Sin1-R81T mutation that leads to hyper-activation of mTORC2 in a mouse xenograft model [20], it will be interesting to further examine whether the Sin1-R81T transgenic mice are prone to develop certain types of tumors.

More importantly, as a heterogeneous disease, cancer initiation and development are commonly driven by multiple genetic alterations or mutations. In addition, after the initial treatment, drug resistance is a commonly developed due to additional adaptive genetic alterations. In this scenario, to effectively cure cancer, targeted or combined cancer therapies emerge as more effective clinical application approaches. For example, application of both Cdk4 and MEK inhibitors not only achieves better treatment outcome, but also reduces drug resistance development in cancer patients [253]. Thus, compound mouse models will shed new lights into which combination of different oncogenic pathways along the PI3K/mTOR/Akt signaling cascade should be considered in a new combination therapy.

Finally, since the traditional radio- or chemo-therapy causes DNA damage that also alters the activation status of the mTOR pathway, it will be critical to examine whether cancer patients benefit from the combination therapy including radio- or chemo-therapy plus targeted inhibition of the mTOR pathway. To examine this hypothesis, genetic mouse models combined with radiation or chemo-drug treatments might need further testing in the future. There is no doubt that biochemical analysis, coupled with comprehensive structural and genetic approaches, significant improvement of our understanding of mTOR biology will be made, which eventually will facilitate the treatment of patients suffering from cancer characterized with aberrancies in the mTOR/Akt oncogenic signaling pathway.

Acknowledgments

The authors sincerely apologize to all those colleagues whose important work was not cited in this paper owing to space limitations. They thank B. North, A. W. Lau, H. Inuzuka, L. Wan and other members of the Wei laboratory for critical reading and discussion of the manuscript. W.W. is an American Cancer Society (ACS) research scholar and a Leukemia & Lymphoma Society (LLS) research scholar. P.L. is supported by grant 1K99CA181342. This work was supported in part by US National Institutes of Health (NIH) grants to W.W. (GM094777 and CA177910).

Abbreviations

mTOR	the mechanistic target of rapamycin or the mammalian target of rapamycin
PIKK	phosphoinositide 3-kinase related protein kinase
ATM	ataxia-telangiectasia mutated
ATR	ataxia-telangiectasia and rad3-related
DNAPK	DNA-dependent protein kinase
Raptor	regulator-associated protein of mammalian target of rapamycin
mLST8	mammalian lethal with sec-13 protein 8
Rictor	rapamycin-insensitive companion of mTOR
mSin1 (MAPKAP1)	mammalian stress-activated map kinase-interacting protein 1
DEPTOR	DEP domain containing mTOR-interacting protein
PRAS40	proline-rich Akt substrate 40 kDa
Protor1/2	protein observed with rictor 1 and 2
SGK	serum/glucocorticoid regulated kinase
4E-BP1	eukaryotic translation initiation factor 4E (eIF4E)-binding protein 1
S6K	S6 kinase
SREBP	sterol regulatory element-binding protein
LKB1	liver kinase B1
TBC1D7	tre2-bub2-cdc16 1 domain family, member 7
AMPK	AMP-activated protein kinase
GAP	GTPase-activating protein
BHD	Birt-Hogg-Dubé
Rheb	ras homolog enriched in brain
FLCN	folliculin
KO	knockout
Tg	transgenic

ODC	ornithine decarboxylase
FGF	fibroblast growth factor
VEGF	vascular endothelial growth factor
HSCs	hematopoietic stem cells
IRS1	insulin receptor substrate 1
IGF-1	insulin-like growth factor
Grb10	growth factor receptor-bound protein 10
FAS	fatty acid synthase
ULK1	uncoordinated 51-like kinase 1
Atg13	mammalian autophagy-related gene 13
DAPI	death-associated protein 1
TFEB	transcription factor EB
ROS	reactive oxygen species
PH	pleckstrin homology
PDK1	phosphoinositide-dependent kinase 1
Pten	phosphatase and tensin homologue
APC	adenomatous polyposis coli
PLD	phospholipase D
REDD1	regulated in development and DNA damage responses 1

References

1. Vezina C, Kudelski A, Sehgal SN. Rapamycin (AY-22,989), a new antifungal antibiotic. I. Taxonomy of the producing streptomycete and isolation of the active principle. *The Journal of antibiotics*. 1975; 28:721–726. [PubMed: 1102508]
2. Heitman J, Movva NR, Hall MN. Targets for cell cycle arrest by the immunosuppressant rapamycin in yeast. *Science*. 1991; 253:905–909. [PubMed: 1715094]
3. Brown EJ, Albers MW, Shin TB, Ichikawa K, Keith CT, Lane WS, Schreiber SL. A mammalian protein targeted by G1-arresting rapamycin-receptor complex. *Nature*. 1994; 369:756–758. [PubMed: 8008069]
4. Sabatini DM, Erdjument-Bromage H, Lui M, Tempst P, Snyder SH. RAFT1: a mammalian protein that binds to FKBP12 in a rapamycin-dependent fashion and is homologous to yeast TORs. *Cell*. 1994; 78:35–43. [PubMed: 7518356]
5. Sabers CJ, Martin MM, Brunn GJ, Williams JM, Dumont FJ, Wiederrecht G, Abraham RT. Isolation of a protein target of the FKBP12-rapamycin complex in mammalian cells. *The Journal of biological chemistry*. 1995; 270:815–822. [PubMed: 7822316]
6. Bakkenist CJ, Kastan MB. Initiating cellular stress responses. *Cell*. 2004; 118:9–17. [PubMed: 15242640]
7. Wullschleger S, Loewith R, Hall MN. TOR signaling in growth and metabolism. *Cell*. 2006; 124:471–484. [PubMed: 16469695]

8. Inoki K, Corradetti MN, Guan KL. Dysregulation of the TSC-mTOR pathway in human disease. *Nature genetics*. 2005; 37:19–24. [PubMed: 15624019]
9. Zoncu R, Efeyan A, Sabatini DM. mTOR: from growth signal integration to cancer, diabetes and ageing. *Nature reviews. Molecular cell biology*. 2011; 12:21–35.
10. Hara K, Maruki Y, Long X, Yoshino K, Oshiro N, Hidayat S, Tokunaga C, Avruch J, Yonezawa K. Raptor, a binding partner of target of rapamycin (TOR), mediates TOR action. *Cell*. 2002; 110:177–189. [PubMed: 12150926]
11. Kim DH, Sarbassov DD, Ali SM, King JE, Latek RR, Erdjument-Bromage H, Tempst P, Sabatini DM. mTOR interacts with raptor to form a nutrient-sensitive complex that signals to the cell growth machinery. *Cell*. 2002; 110:163–175. [PubMed: 12150925]
12. Kim DH, Sarbassov DD, Ali SM, Latek RR, Guntur KV, Erdjument-Bromage H, Tempst P, Sabatini DM. GbetaL a positive regulator of the rapamycin-sensitive pathway required for the nutrient-sensitive interaction between raptor and mTOR. *Molecular cell*. 2003; 11:895–904. [PubMed: 12718876]
13. Jacinto E, Loewith R, Schmidt A, Lin S, Ruegg MA, Hall A, Hall MN. Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin insensitive. *Nature cell biology*. 2004; 6:1122–1128.
14. Sarbassov DD, Ali SM, Kim DH, Guertin DA, Latek RR, Erdjument-Bromage H, Tempst P, Sabatini DM. Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton. *Current biology: CB*. 2004; 14:1296–1302. [PubMed: 15268862]
15. Frias MA, Thoreen CC, Jaffe JD, Schroder W, Sculley T, Carr SA, Sabatini DM. mSin1 is necessary for Akt/PKB phosphorylation, and its isoforms define three distinct mTORC2s. *Current biology: CB*. 2006; 16:1865–1870. [PubMed: 16919458]
16. Jacinto E, Facchinetti V, Liu D, Soto N, Wei S, Jung SY, Huang Q, Qin J, Su B. SIN1/MIP1 maintains rictor-mTOR complex integrity and regulates Akt phosphorylation and substrate specificity. *Cell*. 2006; 127:125–137. [PubMed: 16962653]
17. Laplante M, Sabatini DM. mTOR signaling in growth control and disease. *Cell*. 2012; 149:274–293. [PubMed: 22500797]
18. Guertin DA, Stevens DM, Thoreen CC, Burds AA, Kalaany NY, Moffat J, Brown M, Fitzgerald KJ, Sabatini DM. Ablation in mice of the mTORC components raptor, rictor, or mLST8 reveals that mTORC2 is required for signaling to Akt-FOXO and PKCalpha, but not S6K1. *Developmental cell*. 2006; 11:859–871. [PubMed: 17141160]
19. Yang Q, Inoki K, Ikenoue T, Guan KL. Identification of Sin1 as an essential TORC2 component required for complex formation and kinase activity. *Genes & development*. 2006; 20:2820–2832. [PubMed: 17043309]
20. Liu P, Gan W, Inuzuka H, Lazorchak AS, Gao D, Arojo O, Liu D, Wan L, Zhai B, Yu Y, Yuan M, Kim BM, Shaik S, Menon S, Gygi SP, Lee TH, Asara JM, Manning BD, Blenis J, Su B, Wei W. Sin1 phosphorylation impairs mTORC2 complex integrity and inhibits downstream Akt signalling to suppress tumorigenesis. *Nature cell biology*. 2013; 15:1340–1350.
21. Peterson TR, Laplante M, Thoreen CC, Sancak Y, Kang SA, Kuehl WM, Gray NS, Sabatini DM. DEPTOR is an mTOR inhibitor frequently overexpressed in multiple myeloma cells and required for their survival. *Cell*. 2009; 137:873–886. [PubMed: 19446321]
22. Vander Haar E, Lee SI, Bandhakavi S, Griffin TJ, Kim DH. Insulin signalling to mTOR mediated by the Akt/PKB substrate PRAS40. *Nature cell biology*. 2007; 9:316–323.
23. Wang L, Harris TE, Roth RA, Lawrence JC Jr. PRAS40 regulates mTORC1 kinase activity by functioning as a direct inhibitor of substrate binding. *The Journal of biological chemistry*. 2007; 282:20036–20044. [PubMed: 17510057]
24. Pearce LR, Huang X, Boudeau J, Pawlowski R, Wullschlegel S, Deak M, Ibrahim AF, Gourlay R, Magnuson MA, Alessi DR. Identification of Protor as a novel Rictor-binding component of mTOR complex-2. *The Biochemical journal*. 2007; 405:513–522. [PubMed: 17461779]
25. Pearce LR, Sommer EM, Sakamoto K, Wullschlegel S, Alessi DR. Protor-1 is required for efficient mTORC2-mediated activation of SGK1 in the kidney. *The Biochemical journal*. 2011; 436:169–179. [PubMed: 21413931]

26. Pearce LR, Komander D, Alessi DR. The nuts and bolts of AGC protein kinases. *Nature reviews. Molecular cell biology*. 2010; 11:9–22.
27. Sabatini DM. mTOR and cancer: insights into a complex relationship. *Nature reviews. Cancer*. 2006; 6:729–734.
28. Guertin DA, Sabatini DM. Defining the role of mTOR in cancer. *Cancer cell*. 2007; 12:9–22. [PubMed: 17613433]
29. Cantor JR, Sabatini DM. Cancer cell metabolism: one hallmark, many faces. *Cancer discovery*. 2012; 2:881–898. [PubMed: 23009760]
30. Crino PB, Nathanson KL, Henske EP. The tuberous sclerosis complex. *The New England journal of medicine*. 2006; 355:1345–1356. [PubMed: 17005952]
31. Hemminki A, Markie D, Tomlinson I, Avizienyte E, Roth S, Loukola A, Bignell G, Warren W, Aminoff M, Hoglund P, Jarvinen H, Kristo P, Pelin K, Ridanpaa M, Salovaara R, Toro T, Bodmer W, Olschwang S, Olsen AS, Stratton MR, de la Chapelle A, Aaltonen LA. A serine/threonine kinase gene defective in Peutz-Jeghers syndrome. *Nature*. 1998; 391:184–187. [PubMed: 9428765]
32. Engelman JA, Luo J, Cantley LC. The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism. *Nature reviews. Genetics*. 2006; 7:606–619.
33. Wander SA, Hennessy BT, Slingerland JM. Next-generation mTOR inhibitors in clinical oncology: how pathway complexity informs therapeutic strategy. *The Journal of clinical investigation*. 2011; 121:1231–1241. [PubMed: 21490404]
34. Meric-Bernstam F, Gonzalez-Angulo AM. Targeting the mTOR signaling network for cancer therapy. *Journal of clinical oncology: official journal of the American Society of Clinical Oncology*. 2009; 27:2278–2287. [PubMed: 19332717]
35. Murakami M, Ichisaka T, Maeda M, Oshiro N, Hara K, Edenhofer F, Kiyama H, Yonezawa K, Yamanaka S. mTOR is essential for growth and proliferation in early mouse embryos and embryonic stem cells. *Molecular and cellular biology*. 2004; 24:6710–6718. [PubMed: 15254238]
36. Gangloff YG, Mueller M, Dann SG, Svoboda P, Sticker M, Spetz JF, Um SH, Brown EJ, Cereghini S, Thomas G, Kozma SC. Disruption of the mouse mTOR gene leads to early postimplantation lethality and prohibits embryonic stem cell development. *Molecular and cellular biology*. 2004; 24:9508–9516. [PubMed: 15485918]
37. Wu JJ, Liu J, Chen EB, Wang JJ, Cao L, Narayan N, Fergusson MM, Rovira, Allen M, Springer DA, Lago CU, Zhang S, DuBois W, Ward T, deCabo R, Gavrilova O, Mock B, Finkel T. Increased mammalian lifespan and a segmental and tissue-specific slowing of aging after genetic reduction of mTOR expression. *Cell reports*. 2013; 4:913–920. [PubMed: 23994476]
38. Risson V, Mazelin L, Roceri M, Sanchez H, Moncollin V, Corneloup C, Richard-Bulteau H, Vignaud A, Baas D, Defour A, Freyssen D, Tanti JF, Le-Marchand-Brustel Y, Ferrier B, Conjard-Duplany A, Romanino K, Bauche S, Hantai D, Mueller M, Kozma SC, Thomas G, Ruegg MA, Ferry A, Pende M, Bigard X, Koulmann N, Schaeffer L, Gangloff YG. Muscle inactivation of mTOR causes metabolic and dystrophin defects leading to severe myopathy. *The Journal of cell biology*. 2009; 187:859–874. [PubMed: 20008564]
39. Polak P, Cybulski N, Feige JN, Auwerx J, Ruegg MA, Hall MN. Adipose-specific knockout of raptor results in lean mice with enhanced mitochondrial respiration. *Cell metabolism*. 2008; 8:399–410. [PubMed: 19046571]
40. Bentzinger CF, Romanino K, Cloetta D, Lin S, Mascarenhas JB, Oliveri F, Xia J, Casanova E, Costa CF, Brink M, Zorzato F, Hall MN, Ruegg MA. Skeletal muscle-specific ablation of raptor, but not of rictor, causes metabolic changes and results in muscle dystrophy. *Cell metabolism*. 2008; 8:411–424. [PubMed: 19046572]
41. Shende P, Plaisance I, Morandi C, Pellieux C, Berthonneche C, Zorzato F, Krishnan J, Lerch R, Hall MN, Ruegg MA, Pedrazzini T, Brink M. Cardiac raptor ablation impairs adaptive hypertrophy, alters metabolic gene expression, and causes heart failure in mice. *Circulation*. 2011; 123:1073–1082. [PubMed: 21357822]
42. Cloetta D, Thomanetz V, Baranek C, Lustenberger RM, Lin S, Oliveri F, Atanasoski S, Ruegg MA. Inactivation of mTORC1 in the developing brain causes microcephaly and affects

gliogenesis. The Journal of neuroscience: the official journal of the Society for Neuroscience. 2013; 33:7799–7810. [PubMed: 23637172]

43. Sengupta S, Peterson TR, Laplante M, Oh S, Sabatini DM. mTORC1 controls fasting-induced ketogenesis and its modulation by ageing. *Nature*. 2010; 468:1100–1104. [PubMed: 21179166]
44. Hoshii T, Tadokoro Y, Naka K, Ooshio T, Muraguchi T, Sugiyama N, Soga T, Araki K, Yamamura K, Hirao A. mTORC1 is essential for leukemia propagation but not stem cell self-renewal. *The Journal of clinical investigation*. 2012; 122:2114–2129. [PubMed: 22622041]
45. Shiota C, Woo JT, Lindner J, Shelton KD, Magnuson MA. Multiallelic disruption of the rictor gene in mice reveals that mTOR complex 2 is essential for fetal growth and viability. *Developmental cell*. 2006; 11:583–589. [PubMed: 16962829]
46. Kumar A, Harris TE, Keller SR, Choi KM, Magnuson MA, Lawrence JC Jr. Muscle-specific deletion of rictor impairs insulin-stimulated glucose transport and enhances Basal glycogen synthase activity. *Molecular and cellular biology*. 2008; 28:61–70. [PubMed: 17967879]
47. Yuan M, Pino E, Wu L, Kacergis M, Soukas AA. Identification of Akt-independent regulation of hepatic lipogenesis by mammalian target of rapamycin (mTOR) complex 2. *The Journal of biological chemistry*. 2012; 287:29579–29588. [PubMed: 22773877]
48. Kumar A, Lawrence JC Jr, Jung DY, Ko HJ, Keller SR, Kim JK, Magnuson MA, Harris TE. Fat cell-specific ablation of rictor in mice impairs insulin-regulated fat cell and whole-body glucose and lipid metabolism. *Diabetes*. 2010; 59:1397–1406. [PubMed: 20332342]
49. Carson RP, Fu C, Winzenburger P, Ess KC. Deletion of Rictor in neural progenitor cells reveals contributions of mTORC2 signaling to tuberous sclerosis complex. *Human molecular genetics*. 2013; 22:140–152. [PubMed: 23049074]
50. Siuta MA, Robertson SD, Kocalis H, Saunders C, Gresch PJ, Khatri V, Shiota C, Kennedy JP, Lindsley CW, Daws LC, Polley DB, Veenstra-Vanderweele J, Stanwood GD, Magnuson MA, Niswender KD, Galli A. Dysregulation of the norepinephrine transporter sustains cortical hypodopaminergia and schizophrenia-like behaviors in neuronal rictor null mice. *PLoS biology*. 2010; 8:e1000393. [PubMed: 20543991]
51. Lamming DW, Mihaylova MM, Katajisto P, Baar EL, Yilmaz OH, Hutchins A, Gultekin Y, Gaither R, Sabatini DM. Depletion of Rictor, an essential protein component of mTORC2, decreases male lifespan. *Aging cell*. 2014
52. Guertin DA, Stevens DM, Saitoh M, Kinkel S, Crosby K, Sheen JH, Mullholland DJ, Magnuson MA, Wu H, Sabatini DM. mTOR complex 2 is required for the development of prostate cancer induced by Pten loss in mice. *Cancer cell*. 2009; 15:148–159. [PubMed: 19185849]
53. Lazorchak AS, Liu D, Facchinetti V, Di Lorenzo A, Sessa WC, Schatz DG, Su B. Sin1-mTORC2 suppresses rag and il7r gene expression through Akt2 in B cells. *Molecular cell*. 2010; 39:433–443. [PubMed: 20705244]
54. Chang X, Lazorchak AS, Liu D, Su B. Sin1 regulates Treg-cell development but is not required for T-cell growth and proliferation. *European journal of immunology*. 2012; 42:1639–1647. [PubMed: 22678916]
55. Tee AR, Fingar DC, Manning BD, Kwiatkowski DJ, Cantley LC, Blenis J. Tuberous sclerosis complex-1 and -2 gene products function together to inhibit mammalian target of rapamycin (mTOR)-mediated downstream signaling. *Proceedings of the National Academy of Sciences of the United States of America*. 2002; 99:13571–13576. [PubMed: 12271141]
56. Dibble CC, Elis W, Menon S, Qin W, Klekota J, Asara JM, Finan PM, Kwiatkowski DJ, Murphy LO, Manning BD. TBC1D7 is a third subunit of the TSC1-TSC2 complex upstream of mTORC1. *Molecular cell*. 2012; 47:535–546. [PubMed: 22795129]
57. Inoki K, Li Y, Zhu T, Wu J, Guan KL. TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling. *Nature cell biology*. 2002; 4:648–657.
58. Ma L, Chen Z, Erdjument-Bromage H, Tempst P, Pandolfi PP. Phosphorylation and functional inactivation of TSC2 by Erk implications for tuberous sclerosis and cancer pathogenesis. *Cell*. 2005; 121:179–193. [PubMed: 15851026]
59. Roux PP, Ballif BA, Anjum R, Gygi SP, Blenis J. Tumor-promoting phorbol esters and activated Ras inactivate the tuberous sclerosis tumor suppressor complex via p90 ribosomal S6 kinase.

- Proceedings of the National Academy of Sciences of the United States of America. 2004; 101:13489–13494. [PubMed: 15342917]
60. Menon S, Dibble CC, Talbott G, Hoxhaj G, Valvezan AJ, Takahashi H, Cantley LC, Manning BD. Spatial control of the TSC complex integrates insulin and nutrient regulation of mTORC1 at the lysosome. *Cell*. 2014; 156:771–785. [PubMed: 24529379]
61. Inoki K, Zhu T, Guan KL. TSC2 mediates cellular energy response to control cell growth and survival. *Cell*. 2003; 115:577–590. [PubMed: 14651849]
62. Zoncu R, Bar-Peled L, Efeyan A, Wang S, Sancak Y, Sabatini DM. mTORC1 senses lysosomal amino acids through an inside-out mechanism that requires the vacuolar H(+)-ATPase. *Science*. 2011; 334:678–683. [PubMed: 22053050]
63. Demetriades C, Doumpas N, Teleman AA. Regulation of TORC1 in response to amino acid starvation via lysosomal recruitment of TSC2. *Cell*. 2014; 156:786–799. [PubMed: 24529380]
64. Jozwiak J, Jozwiak S, Wlodarski P. Possible mechanisms of disease development in tuberous sclerosis. *The Lancet. Oncology*. 2008; 9:73–79. [PubMed: 18177819]
65. Kobayashi T, Minowa O, Sugitani Y, Takai S, Mitani H, Kobayashi E, Noda T, Hino O. A germline Tsc1 mutation causes tumor development and embryonic lethality that are similar, but not identical to, those caused by Tsc2 mutation in mice. *Proceedings of the National Academy of Sciences of the United States of America*. 2001; 98:8762–8767. [PubMed: 11438694]
66. Onda H, Lueck A, Marks PW, Warren HB, Kwiatkowski DJ. Tsc2(+/-) mice develop tumors in multiple sites that express gelsolin and are influenced by genetic background. *The Journal of clinical investigation*. 1999; 104:687–695. [PubMed: 10491404]
67. Wilson C, Idziaszczyk S, Parry L, Guy C, Griffiths DF, Lazda E, Bayne RA, Smith AJ, Sampson JR, Cheadle JP. A mouse model of tuberous sclerosis 1 showing background specific early post-natal mortality and metastatic renal cell carcinoma. *Human molecular genetics*. 2005; 14:1839–1850. [PubMed: 15888477]
68. Kladney RD, Cardiff RD, Kwiatkowski DJ, Chiang GG, Weber JD, Arbeit JM, Lu ZH. Tuberous sclerosis complex 1: an epithelial tumor suppressor essential to prevent spontaneous prostate cancer in aged mice. *Cancer research*. 2010; 70:8937–8947. [PubMed: 20940396]
69. Menon S, Yecies JL, Zhang HH, Howell JJ, Nicholatos J, Harputlugil E, Bronson RT, Kwiatkowski DJ, Manning BD. Chronic activation of mTOR complex 1 is sufficient to cause hepatocellular carcinoma in mice. *Science signaling*. 2012; 5:ra24. [PubMed: 22457330]
70. Chen Y, Wei H, Liu F, Guan JL. Hyperactivation of mammalian target of rapamycin complex 1 (mTORC1) promotes breast cancer progression through enhancing glucose starvation-induced autophagy and Akt signaling. *The Journal of biological chemistry*. 2014; 289:1164–1173. [PubMed: 24275666]
71. Kenerson HL, Yeh MM, Kazami M, Jiang X, Riehle KJ, McIntyre RL, Park JO, Kwon S, Campbell JS, Yeung RS. Akt and mTORC1 have different roles during liver tumorigenesis in mice. *Gastroenterology*. 2013; 144:1055–1065. [PubMed: 23376645]
72. Prizant H, Sen A, Light A, Cho SN, DeMayo FJ, Lydon JP, Hammes SR. Uterine-specific loss of Tsc2 leads to myometrial tumors in both the uterus and lungs. *Molecular endocrinology*. 2013; 27:1403–1414. [PubMed: 23820898]
73. Blando J, Portis M, Benavides F, Alexander A, Mills G, Dave B, Conti CJ, Kim J, Walker CL. PTEN deficiency is fully penetrant for prostate adenocarcinoma in C57BL/6 mice via mTOR-dependent growth. *The American journal of pathology*. 2009; 174:1869–1879. [PubMed: 19395652]
74. Saucedo LJ, Gao X, Chiarelli DA, Li L, Pan D, Edgar BA. Rheb promotes cell growth as a component of the insulin/TOR signalling network. *Nature cell biology*. 2003; 5:566–571.
75. Stocker H, Radimerski T, Schindelholtz B, Wittwer F, Belawat P, Daram P, Breuer S, Thomas G, Hafen E. Rheb is an essential regulator of S6K in controlling cell growth in *Drosophila*. *Nature cell biology*. 2003; 5:559–565.
76. Tee AR, Manning BD, Roux PP, Cantley LC, Blenis J. Tuberous sclerosis complex gene products, Tuberin and Hamartin, control mTOR signaling by acting as a GTPase-activating protein complex toward Rheb. *Current biology: CB*. 2003; 13:1259–1268. [PubMed: 12906785]

77. Betz C, Hall MN. Where is mTOR and what is it doing there? *The Journal of cell biology*. 2013; 203:563–574. [PubMed: 24385483]
78. Menon S, Manning BD. Cell signalling: nutrient sensing lost in cancer. *Nature*. 2013; 498:444–445. [PubMed: 23803840]
79. Goorden SM, Hoogveen-Westerveld M, Cheng C, van Woerden GM, Mozaffari M, Post L, Duckers HJ, Nellist M, Elgersma Y. Rheb is essential for murine development. *Molecular and cellular biology*. 2011; 31:1672–1678. [PubMed: 21321084]
80. Zou J, Zhou L, Du XX, Ji Y, Xu J, Tian J, Jiang W, Zou Y, Yu S, Gan L, Luo M, Yang Q, Cui Y, Yang W, Xia X, Chen M, Zhao X, Shen Y, Chen PY, Worley PF, Xiao B. Rheb1 is required for mTORC1 and myelination in postnatal brain development. *Developmental cell*. 2011; 20:97–108. [PubMed: 21238928]
81. Melser S, Chatelain EH, Lavie J, Mahfouf W, Jose C, Obre E, Goorden S, Priault M, Elgersma Y, Rezvani HR, Rossignol R, Benard G. Rheb regulates mitophagy induced by mitochondrial energetic status. *Cell metabolism*. 2013; 17:719–730. [PubMed: 23602449]
82. Mavrakis KJ, Zhu H, Silva RL, Mills JR, Teruya-Feldstein J, Lowe SW, Tam W, Pelletier J, Wendel HG. Tumorigenic activity and therapeutic inhibition of Rheb GTPase. *Genes & development*. 2008; 22:2178–2188. [PubMed: 18708578]
83. Nardella C, Chen Z, Salmena L, Carracedo A, Alimonti A, Egia A, Carver B, Gerald W, Cordon-Cardo C, Pandolfi PP. Aberrant Rheb-mediated mTORC1 activation and Pten haploinsufficiency are cooperative oncogenic events. *Genes & development*. 2008; 22:2172–2177. [PubMed: 18708577]
84. Lu ZH, Shvartsman MB, Lee AY, Shao JM, Murray MM, Kladney RD, Fan D, Krajewski S, Chiang GG, Mills GB, Arbeit JM. Mammalian target of rapamycin activator RHEB is frequently overexpressed in human carcinomas and is critical and sufficient for skin epithelial carcinogenesis. *Cancer research*. 2010; 70:3287–3298. [PubMed: 20388784]
85. Sekiguchi T, Hirose E, Nakashima N, Ii M, Nishimoto T. Novel G proteins, Rag C and Rag D, interact with GTP-binding proteins, Rag A and Rag B. *The Journal of biological chemistry*. 2001; 276:7246–7257. [PubMed: 11073942]
86. Kim E, Goraksha-Hicks P, Li L, Neufeld TP, Guan KL. Regulation of TORC1 by Rag GTPases in nutrient response. *Nature cell biology*. 2008; 10:935–945.
87. Sancak Y, Peterson TR, Shaul YD, Lindquist RA, Thoreen CC, Bar-Peled L, Sabatini DM. The Rag GTPases bind raptor and mediate amino acid signaling to mTORC1. *Science*. 2008; 320:1496–1501. [PubMed: 18497260]
88. Efeyan A, Zoncu R, Chang S, Gumper I, Snitkin H, Wolfson RL, Kirak O, Sabatini DD, Sabatini DM. Regulation of mTORC1 by the Rag GTPases is necessary for neonatal autophagy and survival. *Nature*. 2013; 493:679–683. [PubMed: 23263183]
89. Efeyan A, Schweitzer LD, Bilate AM, Chang S, Kirak O, Lamming DW, Sabatini DM. RagA, but not RagB, is essential for embryonic development and adult mice. *Developmental cell*. 2014; 29:321–329. [PubMed: 24768164]
90. Kim YC, Park HW, Sciarretta S, Mo JS, Jewell JL, Russell RC, Wu X, Sadoshima J, Guan KL. Rag GTPases are cardioprotective by regulating lysosomal function. *Nature communications*. 2014; 5:4241.
91. Tsun ZY, Bar-Peled L, Chantranupong L, Zoncu R, Wang T, Kim C, Spooner E, Sabatini DM. The folliculin tumor suppressor is a GAP for the RagC/D GTPases that signal amino acid levels to mTORC1. *Molecular cell*. 2013; 52:495–505. [PubMed: 24095279]
92. Bar-Peled L, Chantranupong L, Cherniack AD, Chen WW, Ottina KA, Grabiner BC, Spear ED, Carter SL, Meyerson M, Sabatini DM. A Tumor suppressor complex with GAP activity for the Rag GTPases that signal amino acid sufficiency to mTORC1. *Science*. 2013; 340:1100–1106. [PubMed: 23723238]
93. Hardie DG, Alessi DR. LKB1 and AMPK and the cancer-metabolism link - ten years after. *BMC biology*. 2013; 11:36. [PubMed: 23587167]
94. Mihaylova MM, Shaw RJ. The AMPK signalling pathway coordinates cell growth, autophagy and metabolism. *Nature cell biology*. 2011; 13:1016–1023.

95. Hardie DG. AMP-activated/SNF1 protein kinases: conserved guardians of cellular energy. *Nature reviews. Molecular cell biology*. 2007; 8:774–785.
96. Gwinn DM, Shackelford DB, Egan DF, Mihaylova MM, Mery A, Vasquez DS, Turk BE, Shaw RJ. AMPK phosphorylation of raptor mediates a metabolic checkpoint. *Molecular cell*. 2008; 30:214–226. [PubMed: 18439900]
97. Viollet B, Athes Y, Mounier R, Guigas B, Zarrinpashneh E, Horman S, Lantier L, Hebrard S, Devin-Leclerc J, Beauloye C, Foretz M, Andreelli F, Ventura-Clapier R, Bertrand L. AMPK: Lessons from transgenic and knockout animals. *Frontiers in bioscience*. 2009; 14:19–44.
98. Lantier L, Mounier R, Leclerc J, Pende M, Foretz M, Viollet B. Coordinated maintenance of muscle cell size control by AMP-activated protein kinase. *FASEB journal: official publication of the Federation of American Societies for Experimental Biology*. 2010; 24:3555–3561. [PubMed: 20460585]
99. Viollet B, Andreelli F, Jorgensen SB, Perrin C, Geloën A, Flamez D, Mu J, Lenzner C, Baud O, Bennoun M, Gomas E, Nicolas G, Wojtaszewski JF, Kahn A, Carling D, Schuit FC, Birnbaum MJ, Richter EA, Burcelin R, Vaulont S. The AMP-activated protein kinase $\alpha 2$ catalytic subunit controls whole-body insulin sensitivity. *The Journal of clinical investigation*. 2003; 111:91–98. [PubMed: 12511592]
100. Kang H, Viollet B, Wu D. Genetic deletion of catalytic subunits of AMP-activated protein kinase increases osteoclasts and reduces bone mass in young adult mice. *The Journal of biological chemistry*. 2013; 288:12187–12196. [PubMed: 23486478]
101. Barnes BR, Marklund S, Steiler TL, Walter M, Hjalms G, Amarger V, Mahlapuu M, Leng Y, Johansson C, Galuska D, Lindgren K, Abrink M, Stapleton D, Zierath JR, Andersson L. The 5'-AMP-activated protein kinase $\gamma 3$ isoform has a key role in carbohydrate and lipid metabolism in glycolytic skeletal muscle. *The Journal of biological chemistry*. 2004; 279:38441–38447. [PubMed: 15247217]
102. O'Neill HM, Maarbjerg SJ, Crane JD, Jeppesen J, Jorgensen SB, Schertzer JD, Shyroka O, Kiens B, van Denderen BJ, Tarnopolsky MA, Kemp BE, Richter EA, Steinberg GR. AMP-activated protein kinase (AMPK) $\beta 1\beta 2$ muscle null mice reveal an essential role for AMPK in maintaining mitochondrial content and glucose uptake during exercise. *Proceedings of the National Academy of Sciences of the United States of America*. 2011; 108:16092–16097. [PubMed: 21896769]
103. Zhou G, Myers R, Li Y, Chen Y, Shen X, Fenyk-Melody J, Wu M, Ventre J, Doebber T, Fujii N, Musi N, Hirshman MF, Goodyear LJ, Moller DE. Role of AMP-activated protein kinase in mechanism of metformin action. *The Journal of clinical investigation*. 2001; 108:1167–1174. [PubMed: 11602624]
104. Evans JM, Donnelly LA, Emslie-Smith AM, Alessi DR, Morris AD. Metformin and reduced risk of cancer in diabetic patients. *BMJ*. 2005; 330:1304–1305. [PubMed: 15849206]
105. Faubert B, Boily G, Izreig S, Griss T, Samborska B, Dong Z, Dupuy F, Chambers C, Fuerth BJ, Viollet B, Mamer OA, Avizonis D, DeBerardinis RJ, Siegel PM, Jones RG. AMPK is a negative regulator of the Warburg effect and suppresses tumor growth in vivo. *Cell metabolism*. 2013; 17:113–124. [PubMed: 23274086]
106. Phoenix KN, Devarakonda CV, Fox MM, Stevens LE, Claffey KP. AMPK $\alpha 2$ Suppresses Murine Embryonic Fibroblast Transformation and Tumorigenesis. *Genes & cancer*. 2012; 3:51–62. [PubMed: 22893790]
107. Jeon SM, Chandel NS, Hay N. AMPK regulates NADPH homeostasis to promote tumour cell survival during energy stress. *Nature*. 2012; 485:661–665. [PubMed: 22660331]
108. Kwiatkowski DJ, Zhang H, Bandura JL, Heiberger KM, Glogauer M, el-Hashemite N, Onda H. A mouse model of TSC1 reveals sex-dependent lethality from liver hemangiomas, and up-regulation of p70S6 kinase activity in Tsc1 null cells. *Human molecular genetics*. 2002; 11:525–534. [PubMed: 11875047]
109. Castets P, Rugg MA. MTORC1 determines autophagy through ULK1 regulation in skeletal muscle. *Autophagy*. 2013; 9:1435–1437. [PubMed: 23896646]
110. Wu J, Yang J, Yang K, Wang H, Gorentla B, Shin J, Qiu Y, Que LG, Foster WM, Xia Z, Chi H, Zhong XP. iNKT cells require TSC1 for terminal maturation and effector lineage fate decisions. *The Journal of clinical investigation*. 2014; 124:1685–1698. [PubMed: 24614103]

111. Malhowski AJ, Hira H, Bashiruddin S, Warburton R, Goto J, Robert B, Kwiatkowski DJ, Finlay GA. Smooth muscle protein-22-mediated deletion of Tsc1 results in cardiac hypertrophy that is mTORC1-mediated and reversed by rapamycin. *Human molecular genetics*. 2011; 20:1290–1305. [PubMed: 21212099]
112. Mori H, Inoki K, Munzberg H, Opland D, Faouzi M, Villanueva EC, Ikenoue T, Kwiatkowski D, MacDougald OA, Myers MG Jr, Guan KL. Critical role for hypothalamic mTOR activity in energy balance. *Cell metabolism*. 2009; 9:362–374. [PubMed: 19356717]
113. Zeng LH, Xu L, Gutmann DH, Wong M. Rapamycin prevents epilepsy in a mouse model of tuberous sclerosis complex. *Annals of neurology*. 2008; 63:444–453. [PubMed: 18389497]
114. Kobayashi T, Minowa O, Kuno J, Mitani H, Hino O, Noda T. Renal carcinogenesis, hepatic hemangiomatosis, and embryonic lethality caused by a germ-line Tsc2 mutation in mice. *Cancer research*. 1999; 59:1206–1211. [PubMed: 10096549]
115. Yuan E, Tsai PT, Greene-Colozzi E, Sahin M, Kwiatkowski DJ, Malinowska IA. Graded loss of tuberin in an allelic series of brain models of TSC correlates with survival, and biochemical, histological and behavioral features. *Human molecular genetics*. 2012; 21:4286–4300. [PubMed: 22752306]
116. Tartarin P, Guibert E, Toure A, Ouiste C, Leclerc J, Sanz N, Briere S, Dacheux JL, Delaleu B, McNeilly JR, McNeilly AS, Brillard JP, Dupont J, Foretz M, Viollet B, Froment P. Inactivation of AMPK α 1 induces asthenozoospermia and alters spermatozoa morphology. *Endocrinology*. 2012; 153:3468–3481. [PubMed: 22581459]
117. Dzamko N, van Denderen BJ, Hevener AL, Jorgensen SB, Honeyman J, Galic S, Chen ZP, Watt MJ, Campbell DJ, Steinberg GR, Kemp BE. AMPK β 1 deletion reduces appetite preventing obesity and hepatic insulin resistance. *The Journal of biological chemistry*. 2010; 285:115–122. [PubMed: 19892703]
118. Steinberg GR, O'Neill HM, Dzamko NL, Galic S, Naim T, Koopman R, Jorgensen SB, Honeyman J, Hewitt K, Chen ZP, Schertzer JD, Scott JW, Koentgen F, Lynch GS, Watt MJ, van Denderen BJ, Campbell DJ, Kemp BE. Whole body deletion of AMP-activated protein kinase β 2 reduces muscle AMPK activity and exercise capacity. *The Journal of biological chemistry*. 2010; 285:37198–37209. [PubMed: 20855892]
119. Thomas MM, Wang DC, D'Souza DM, Krause MP, Layne AS, Criswell DS, O'Neill HM, Connor MK, Anderson JE, Kemp BE, Steinberg GR, Hawke TJ. Muscle-specific AMPK β 1 β 2-null mice display a myopathy due to loss of capillary density in nonpostural muscles. *FASEB journal: official publication of the Federation of American Societies for Experimental Biology*. 2014; 28:2098–2107. [PubMed: 24522207]
120. Ma XM, Blenis J. Molecular mechanisms of mTOR-mediated translational control. *Nature reviews. Molecular cell biology*. 2009; 10:307–318.
121. Hay N, Sonenberg N. Upstream and downstream of mTOR. *Genes & development*. 2004; 18:1926–1945. [PubMed: 15314020]
122. Zhang Y, Nicholatos J, Dreier JR, Ricoult SJ, Widenmaier SB, Hotamisligil GS, Kwiatkowski DJ, Manning BD. Coordinated regulation of protein synthesis and degradation by mTORC1. *Nature*. 2014; 513:440–443. [PubMed: 25043031]
123. Richter JD, Sonenberg N. Regulation of cap-dependent translation by eIF4E inhibitory proteins. *Nature*. 2005; 433:477–480. [PubMed: 15690031]
124. Mamane Y, Petroulakis E, Rong L, Yoshida K, Ler LW, Sonenberg N. eIF4E--from translation to transformation. *Oncogene*. 2004; 23:3172–3179. [PubMed: 15094766]
125. Tsukiyama-Kohara K, Poulin F, Kohara M, DeMaria CT, Cheng A, Wu Z, Gingras AC, Katsume A, Elchebly M, Spiegelman BM, Harper ME, Tremblay ML, Sonenberg N. Adipose tissue reduction in mice lacking the translational inhibitor 4E-BP1. *Nature medicine*. 2001; 7:1128–1132.
126. Le Bacquer O, Petroulakis E, Pagliarunga S, Poulin F, Richard D, Cianflone K, Sonenberg N. Elevated sensitivity to diet-induced obesity and insulin resistance in mice lacking 4E-BP1 and 4E-BP2. *The Journal of clinical investigation*. 2007; 117:387–396. [PubMed: 17273556]

127. Olson KE, Booth GC, Poulin F, Sonenberg N, Beretta L. Impaired myelopoiesis in mice lacking the repressors of translation initiation, 4E-BP1 and 4E-BP2. *Immunology*. 2009; 128:e376–384. [PubMed: 19175792]
128. Wendel HG, De Stanchina E, Fridman JS, Malina A, Ray S, Kogan S, Cordon-Cardo C, Pelletier J, Lowe SW. Survival signalling by Akt and eIF4E in oncogenesis and cancer therapy. *Nature*. 2004; 428:332–337. [PubMed: 15029198]
129. Petroulakis E, Parsyan A, Dowling RJ, LeBacquer O, Martineau Y, Bidinosti M, Larsson O, Alain T, Rong L, Mamane Y, Paquet M, Furic L, Topisirovic I, Shahbazian D, Livingstone M, Costa-Mattioli M, Teodoro JG, Sonenberg N. p53-dependent translational control of senescence and transformation via 4E-BPs. *Cancer cell*. 2009; 16:439–446. [PubMed: 19878875]
130. She QB, Halilovic E, Ye Q, Zhen W, Shirasawa S, Sasazuki T, Solit DB, Rosen N. 4E-BP1 is a key effector of the oncogenic activation of the AKT and ERK signaling pathways that integrates their function in tumors. *Cancer cell*. 2010; 18:39–51. [PubMed: 20609351]
131. Grove JR, Banerjee P, Balasubramanyam A, Coffey PJ, Price DJ, Avruch J, Woodgett JR. Cloning and expression of two human p70 S6 kinase polypeptides differing only at their amino termini. *Molecular and cellular biology*. 1991; 11:5541–5550. [PubMed: 1922062]
132. Reinhard C, Thomas G, Kozma SC. A single gene encodes two isoforms of the p70 S6 kinase: activation upon mitogenic stimulation. *Proceedings of the National Academy of Sciences of the United States of America*. 1992; 89:4052–4056. [PubMed: 1570332]
133. Shima H, Pende M, Chen Y, Fumagalli S, Thomas G, Kozma SC. Disruption of the p70(s6k)/p85(s6k) gene reveals a small mouse phenotype and a new functional S6 kinase. *The EMBO journal*. 1998; 17:6649–6659. [PubMed: 9822608]
134. Pende M, Um SH, Mieulet V, Sticker M, Goss VL, Mestan J, Mueller M, Fumagalli S, Kozma SC, Thomas G. S6K1(–/–)/S6K2(–/–) mice exhibit perinatal lethality and rapamycin-sensitive 5'-terminal oligopyrimidine mRNA translation and reveal a mitogen-activated protein kinase-dependent S6 kinase pathway. *Molecular and cellular biology*. 2004; 24:3112–3124. [PubMed: 15060135]
135. Pende M, Kozma SC, Jaquet M, Oorschot V, Burcelin R, Le Marchand-Brustel Y, Klumperman J, Thorens B, Thomas G. Hypoinsulinaemia, glucose intolerance and diminished beta-cell size in S6K1-deficient mice. *Nature*. 2000; 408:994–997. [PubMed: 11140689]
136. Um SH, Frigerio F, Watanabe M, Picard F, Joaquin M, Sticker M, Fumagalli S, Allegrini PR, Kozma SC, Auwerx J, Thomas G. Absence of S6K1 protects against age- and diet-induced obesity while enhancing insulin sensitivity. *Nature*. 2004; 431:200–205. [PubMed: 15306821]
137. Um SH, D'Alessio D, Thomas G. Nutrient overload, insulin resistance, and ribosomal protein S6 kinase 1, S6K1. *Cell metabolism*. 2006; 3:393–402. [PubMed: 16753575]
138. Hsu PP, Kang SA, Rameseder J, Zhang Y, Ottina KA, Lim D, Peterson TR, Choi Y, Gray NS, Yaffe MB, Marto JA, Sabatini DM. The mTOR-regulated phosphoproteome reveals a mechanism of mTORC1-mediated inhibition of growth factor signaling. *Science*. 2011; 332:1317–1322. [PubMed: 21659604]
139. Yu Y, Yoon SO, Poulogiannis G, Yang Q, Ma XM, Villen J, Kubica N, Hoffman GR, Cantley LC, Gygi SP, Blenis J. Phosphoproteomic analysis identifies Grb10 as an mTORC1 substrate that negatively regulates insulin signaling. *Science*. 2011; 332:1322–1326. [PubMed: 21659605]
140. Ye J, DeBose-Boyd RA. Regulation of cholesterol and fatty acid synthesis. *Cold Spring Harbor perspectives in biology*. 2011; 3
141. Duvel K, Yecies JL, Menon S, Raman P, Lipovsky AI, Souza AL, Triantafellow E, Ma Q, Gorski R, Cleaver S, Vander Heiden MG, MacKeigan JP, Finan PM, Clish CB, Murphy LO, Manning BD. Activation of a metabolic gene regulatory network downstream of mTOR complex 1. *Molecular cell*. 2010; 39:171–183. [PubMed: 20670887]
142. Shao W, Espenshade PJ. Expanding roles for SREBP in metabolism. *Cell metabolism*. 2012; 16:414–419. [PubMed: 23000402]
143. Peterson TR, Sengupta SS, Harris TE, Carmack AE, Kang SA, Balderas E, Guertin DA, Madden KL, Carpenter AE, Finck BN, Sabatini DM. mTOR complex 1 regulates lipin 1 localization to control the SREBP pathway. *Cell*. 2011; 146:408–420. [PubMed: 21816276]

144. Brown MS, Goldstein JL. The SREBP pathway: regulation of cholesterol metabolism by proteolysis of a membrane-bound transcription factor. *Cell*. 1997; 89:331–340. [PubMed: 9150132]
145. Shimano H, Shimomura I, Hammer RE, Herz J, Goldstein JL, Brown MS, Horton JD. Elevated levels of SREBP-2 and cholesterol synthesis in livers of mice homozygous for a targeted disruption of the SREBP-1 gene. *The Journal of clinical investigation*. 1997; 100:2115–2124. [PubMed: 9329978]
146. Liang G, Yang J, Horton JD, Hammer RE, Goldstein JL, Brown MS. Diminished hepatic response to fasting/refeeding and liver X receptor agonists in mice with selective deficiency of sterol regulatory element-binding protein-1c. *The Journal of biological chemistry*. 2002; 277:9520–9528. [PubMed: 11782483]
147. Shimano H, Horton JD, Hammer RE, Shimomura I, Brown MS, Goldstein JL. Overproduction of cholesterol and fatty acids causes massive liver enlargement in transgenic mice expressing truncated SREBP-1a. *The Journal of clinical investigation*. 1996; 98:1575–1584. [PubMed: 8833906]
148. Shimano H, Horton JD, Shimomura I, Hammer RE, Brown MS, Goldstein JL. Isoform 1c of sterol regulatory element binding protein is less active than isoform 1a in livers of transgenic mice and in cultured cells. *The Journal of clinical investigation*. 1997; 99:846–854. [PubMed: 9062341]
149. Menendez JA, Lupu R. Fatty acid synthase and the lipogenic phenotype in cancer pathogenesis. *Nature reviews. Cancer*. 2007; 7:763–777.
150. Freed-Pastor WA, Mizuno H, Zhao X, Langerod A, Moon SH, Rodriguez-Barrueco R, Barsotti A, Chicas A, Li W, Polotskaia A, Bissell MJ, Osborne TF, Tian B, Lowe SW, Silva JM, Borresen-Dale AL, Levine AJ, Bargonetti J, Prives C. Mutant p53 disrupts mammary tissue architecture via the mevalonate pathway. *Cell*. 2012; 148:244–258. [PubMed: 22265415]
151. Bolender RP, Weibel ER. A morphometric study of the removal of phenobarbital-induced membranes from hepatocytes after cessation of threatment. *The Journal of cell biology*. 1973; 56:746–761. [PubMed: 4569312]
152. Jewell JL, Russell RC, Guan KL. Amino acid signalling upstream of mTOR. *Nature reviews. Molecular cell biology*. 2013; 14:133–139.
153. Yang Z, Klionsky DJ. Eaten alive: a history of macroautophagy. *Nature cell biology*. 2010; 12:814–822.
154. Koren I, Reem E, Kimchi A. DAP1, a novel substrate of mTOR, negatively regulates autophagy. *Current biology: CB*. 2010; 20:1093–1098. [PubMed: 20537536]
155. Martina JA, Chen Y, Gucek M, Puertollano R. MTORC1 functions as a transcriptional regulator of autophagy by preventing nuclear transport of TFEB. *Autophagy*. 2012; 8:903–914. [PubMed: 22576015]
156. Steingrimsson E, Tessarollo L, Reid SW, Jenkins NA, Copeland NG. The bHLH-Zip transcription factor Tfeb is essential for placental vascularization. *Development*. 1998; 125:4607–4616. [PubMed: 9806910]
157. Kundu M, Lindsten T, Yang CY, Wu J, Zhao F, Zhang J, Selak MA, Ney PA, Thompson CB. Ulk1 plays a critical role in the autophagic clearance of mitochondria and ribosomes during reticulocyte maturation. *Blood*. 2008; 112:1493–1502. [PubMed: 18539900]
158. Qu X, Yu J, Bhagat G, Furuya N, Hibshoosh H, Troxel A, Rosen J, Eskelinen EL, Mizushima N, Ohsumi Y, Cattoretti G, Levine B. Promotion of tumorigenesis by heterozygous disruption of the beclin 1 autophagy gene. *The Journal of clinical investigation*. 2003; 112:1809–1820. [PubMed: 14638851]
159. Amaravadi RK, Yu D, Lum JJ, Bui T, Christophorou MA, Evan GI, Thomas-Tikhonenko A, Thompson CB. Autophagy inhibition enhances therapy-induced apoptosis in a Myc-induced model of lymphoma. *The Journal of clinical investigation*. 2007; 117:326–336. [PubMed: 17235397]
160. Horton JD, Goldstein JL, Brown MS. SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver. *The Journal of clinical investigation*. 2002; 109:1125–1131. [PubMed: 11994399]

161. Ferron M, Settembre C, Shimazu J, Lacombe J, Kato S, Rawlings DJ, Ballabio A, Karsenty G. A RANKL-PKCbeta-TFEB signaling cascade is necessary for lysosomal biogenesis in osteoclasts. *Genes & development*. 2013; 27:955–969. [PubMed: 23599343]
162. Manning BD, Cantley LC. AKT/PKB signaling: navigating downstream. *Cell*. 2007; 129:1261–1274. [PubMed: 17604717]
163. Hay N. The Akt-mTOR tango and its relevance to cancer. *Cancer cell*. 2005; 8:179–183. [PubMed: 16169463]
164. Toker A, Yoeli-Lerner M. Akt signaling and cancer: surviving but not moving on. *Cancer research*. 2006; 66:3963–3966. [PubMed: 16618711]
165. Konishi H, Kuroda S, Tanaka M, Matsuzaki H, Ono Y, Kameyama K, Haga T, Kikkawa U. Molecular cloning and characterization of a new member of the RAC protein kinase family: association of the pleckstrin homology domain of three types of RAC protein kinase with protein kinase C subspecies and beta gamma subunits of G proteins. *Biochemical and biophysical research communications*. 1995; 216:526–534. [PubMed: 7488143]
166. Fayard E, Tintignac LA, Baudry A, Hemmings BA. Protein kinase B/Akt at a glance. *Journal of cell science*. 2005; 118:5675–5678. [PubMed: 16339964]
167. Toker A. Achieving specificity in Akt signaling in cancer. *Advances in biological regulation*. 2012; 52:78–87. [PubMed: 21986444]
168. Alessi DR, James SR, Downes CP, Holmes AB, Gaffney PR, Reese CB, Cohen P. Characterization of a 3-phosphoinositide-dependent protein kinase which phosphorylates and activates protein kinase Balpha. *Current biology: CB*. 1997; 7:261–269. [PubMed: 9094314]
169. Sarbassov DD, Guertin DA, Ali SM, Sabatini DM. Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. *Science*. 2005; 307:1098–1101. [PubMed: 15718470]
170. Gonzalez E, McGraw TE. The Akt kinases: isoform specificity in metabolism and cancer. *Cell cycle*. 2009; 8:2502–2508. [PubMed: 19597332]
171. Manning BD, Tee AR, Logsdon MN, Blenis J, Cantley LC. Identification of the tuberous sclerosis complex-2 tumor suppressor gene product tuberlin as a target of the phosphoinositide 3-kinase/akt pathway. *Molecular cell*. 2002; 10:151–162. [PubMed: 12150915]
172. Liu P, Begley M, Michowski W, Inuzuka H, Ginzberg M, Gao D, Tsou P, Gan W, Papa A, Kim BM, Wan L, Singh A, Zhai B, Yuan M, Wang Z, Gygi SP, Lee TH, Lu KP, Toker A, Pandolfi PP, Asara JM, Kirschner MW, Sicinski P, Cantley L, Wei W. Cell-cycle-regulated activation of Akt kinase by phosphorylation at its carboxyl terminus. *Nature*. 2014; 508:541–545. [PubMed: 24670654]
173. Cho H, Thorvaldsen JL, Chu Q, Feng F, Birnbaum MJ. Akt1/PKBalpha is required for normal growth but dispensable for maintenance of glucose homeostasis in mice. *The Journal of biological chemistry*. 2001; 276:38349–38352. [PubMed: 11533044]
174. Cho H, Mu J, Kim JK, Thorvaldsen JL, Chu Q, Crenshaw EB 3rd, Kaestner KH, Bartolomei MS, Shulman GI, Birnbaum MJ. Insulin resistance and a diabetes mellitus-like syndrome in mice lacking the protein kinase Akt2 (PKB beta). *Science*. 2001; 292:1728–1731. [PubMed: 11387480]
175. Easton RM, Cho H, Roovers K, Shineman DW, Mizrahi M, Forman MS, Lee VM, Szabolcs M, de Jong R, Oltersdorf T, Ludwig T, Efstratiadis A, Birnbaum MJ. Role for Akt3/protein kinase Bgamma in attainment of normal brain size. *Molecular and cellular biology*. 2005; 25:1869–1878. [PubMed: 15713641]
176. Chen WS, Xu PZ, Gottlob K, Chen ML, Sokol K, Shiyanova T, Roninson I, Weng W, Suzuki R, Tobe K, Kadowaki T, Hay N. Growth retardation and increased apoptosis in mice with homozygous disruption of the Akt1 gene. *Genes & development*. 2001; 15:2203–2208. [PubMed: 11544177]
177. Garofalo RS, Orena SJ, Rafidi K, Torchia AJ, Stock JL, Hildebrandt AL, Coskran T, Black SC, Brees DJ, Wicks JR, McNeish JD, Coleman KG. Severe diabetes, age-dependent loss of adipose tissue, and mild growth deficiency in mice lacking Akt2/PKB beta. *The Journal of clinical investigation*. 2003; 112:197–208. [PubMed: 12843127]
178. Tschopp O, Yang ZZ, Brodbeck D, Dummmler BA, Hemmings-Mieszczak M, Watanabe T, Michaelis T, Frahm J, Hemmings BA. Essential role of protein kinase B gamma (PKB gamma/

- Akt3) in postnatal brain development but not in glucose homeostasis. *Development*. 2005; 132:2943–2954. [PubMed: 15930105]
179. Yang ZZ, Tschopp O, Di-Poi N, Bruder E, Baudry A, Dummler B, Wahli W, Hemmings BA. Dosage-dependent effects of Akt1/protein kinase Balpha (PKBalpha) and Akt3/PKBgamma on thymus, skin, and cardiovascular and nervous system development in mice. *Molecular and cellular biology*. 2005; 25:10407–10418. [PubMed: 16287854]
 180. Peng XD, Xu PZ, Chen ML, Hahn-Windgassen A, Skeen J, Jacobs J, Sundararajan D, Chen WS, Crawford SE, Coleman KG, Hay N. Dwarfism, impaired skin development, skeletal muscle atrophy, delayed bone development, and impeded adipogenesis in mice lacking Akt1 and Akt2. *Genes & development*. 2003; 17:1352–1365. [PubMed: 12782654]
 181. Dummler B, Tschopp O, Hynx D, Yang ZZ, Dirnhofer S, Hemmings BA. Life with a single isoform of Akt: mice lacking Akt2 and Akt3 are viable but display impaired glucose homeostasis and growth deficiencies. *Molecular and cellular biology*. 2006; 26:8042–8051. [PubMed: 16923958]
 182. Carpten JD, Faber AL, Horn C, Donoho GP, Briggs SL, Robbins CM, Hostetter G, Boguslawski S, Moses TY, Savage S, Uhlik M, Lin A, Du J, Qian YW, Zeckner DJ, Tucker-Kellogg G, Touchman J, Patel K, Mousses S, Bittner M, Schevitz R, Lai MH, Blanchard KL, Thomas JE. A transforming mutation in the pleckstrin homology domain of AKT1 in cancer. *Nature*. 2007; 448:439–444. [PubMed: 17611497]
 183. Campbell IG, Russell SE, Choong DY, Montgomery KG, Ciavarella ML, Hooi CS, Cristiano BE, Pearson RB, Phillips WA. Mutation of the PIK3CA gene in ovarian and breast cancer. *Cancer research*. 2004; 64:7678–7681. [PubMed: 15520168]
 184. Samuels Y, Wang Z, Bardelli A, Silliman N, Ptak J, Szabo S, Yan H, Gazdar A, Powell SM, Riggins GJ, Willson JK, Markowitz S, Kinzler KW, Vogelstein B, Velculescu VE. High frequency of mutations of the PIK3CA gene in human cancers. *Science*. 2004; 304:554. [PubMed: 15016963]
 185. Lee JW, Soung YH, Kim SY, Lee HW, Park WS, Nam SW, Kim SH, Lee JY, Yoo NJ, Lee SH. PIK3CA gene is frequently mutated in breast carcinomas and hepatocellular carcinomas. *Oncogene*. 2005; 24:1477–1480. [PubMed: 15608678]
 186. Levine DA, Bogomolny F, Yee CJ, Lash A, Barakat RR, Borgen PI, Boyd J. Frequent mutation of the PIK3CA gene in ovarian and breast cancers. *Clinical cancer research: an official journal of the American Association for Cancer Research*. 2005; 11:2875–2878. [PubMed: 15837735]
 187. Cantley LC, Neel BG. New insights into tumor suppression: PTEN suppresses tumor formation by restraining the phosphoinositide 3-kinase/AKT pathway. *Proceedings of the National Academy of Sciences of the United States of America*. 1999; 96:4240–4245. [PubMed: 10200246]
 188. Banerji S, Cibulskis K, Rangel-Escareno C, Brown KK, Carter SL, Frederick AM, Lawrence MS, Sivachenko AY, Sougnez C, Zou L, Cortes ML, Fernandez-Lopez JC, Peng S, Ardlie KG, Auclair D, Bautista-Pina V, Duke F, Francis J, Jung J, Maffuz-Aziz A, Onofrio RC, Parkin M, Pho NH, Quintanar-Jurado V, Ramos AH, Rebollar-Vega R, Rodriguez-Cuevas S, Romero-Cordoba SL, Schumacher SE, Stransky N, Thompson KM, Uribe-Figueroa L, Baselga J, Beroukhi R, Polyak K, Sgroi DC, Richardson AL, Jimenez-Sanchez G, Lander ES, Gabriel SB, Garraway LA, Golub TR, Melendez-Zajgla J, Toker A, Getz G, Hidalgo-Miranda A, Meyerson M. Sequence analysis of mutations and translocations across breast cancer subtypes. *Nature*. 2012; 486:405–409. [PubMed: 22722202]
 189. Maroulakou IG, Oemler W, Naber SP, Tschlis PN. Akt1 ablation inhibits, whereas Akt2 ablation accelerates the development of mammary adenocarcinomas in mouse mammary tumor virus (MMTV)-ErbB2/neu and MMTV-polyoma middle T transgenic mice. *Cancer research*. 2007; 67:167–177. [PubMed: 17210696]
 190. Dillon RL, Marcotte R, Hennessy BT, Woodgett JR, Mills GB, Muller WJ. Akt1 and akt2 play distinct roles in the initiation and metastatic phases of mammary tumor progression. *Cancer research*. 2009; 69:5057–5064. [PubMed: 19491266]
 191. Parker PJ, Murray-Rust J. PKC at a glance. *Journal of cell science*. 2004; 117:131–132. [PubMed: 14676268]

192. Meier M, Menne J, Haller H. Targeting the protein kinase C family in the diabetic kidney: lessons from analysis of mutant mice. *Diabetologia*. 2009; 52:765–775. [PubMed: 19238353]
193. Chen L, Hahn H, Wu G, Chen CH, Liron T, Schechtman D, Cavallaro G, Banci L, Guo Y, Bolli R, Dorn GW 2nd, Mochly-Rosen D. Opposing cardioprotective actions and parallel hypertrophic effects of delta PKC and epsilon PKC. *Proceedings of the National Academy of Sciences of the United States of America*. 2001; 98:11114–11119. [PubMed: 11553773]
194. Menne J, Park JK, Boehne M, Elger M, Lindschau C, Kirsch T, Meier M, Gueler F, Fiebeler A, Bahlmann FH, Leitges M, Haller H. Diminished loss of proteoglycans and lack of albuminuria in protein kinase C-alpha-deficient diabetic mice. *Diabetes*. 2004; 53:2101–2109. [PubMed: 15277392]
195. Leitges M, Schmedt C, Guinamard R, Davoust J, Schaal S, Stabel S, Tarakhovsky A. Immunodeficiency in protein kinase cbeta-deficient mice. *Science*. 1996; 273:788–791. [PubMed: 8670417]
196. Abeliovich A, Chen C, Goda Y, Silva AJ, Stevens CF, Tonegawa S. Modified hippocampal long-term potentiation in PKC gamma-mutant mice. *Cell*. 1993; 75:1253–1262. [PubMed: 8269509]
197. Abeliovich A, Paylor R, Chen C, Kim JJ, Wehner JM, Tonegawa S. PKC gamma mutant mice exhibit mild deficits in spatial and contextual learning. *Cell*. 1993; 75:1263–1271. [PubMed: 8269510]
198. Mecklenbrauker I, Saijo K, Zheng NY, Leitges M, Tarakhovsky A. Protein kinase Cdelta controls self-antigen-induced B-cell tolerance. *Nature*. 2002; 416:860–865. [PubMed: 11976687]
199. Miyamoto A, Nakayama K, Imaki H, Hirose S, Jiang Y, Abe M, Tsukiyama T, Nagahama H, Ohno S, Hatakeyama S, Nakayama KI. Increased proliferation of B cells and auto-immunity in mice lacking protein kinase Cdelta. *Nature*. 2002; 416:865–869. [PubMed: 11976687]
200. Khasar SG, Lin YH, Martin A, Dadgar J, McMahon T, Wang D, Hundle B, Aley KO, Isenberg W, McCarter G, Green PG, Hodge CW, Levine JD, Messing RO. A novel nociceptor signaling pathway revealed in protein kinase C epsilon mutant mice. *Neuron*. 1999; 24:253–260. [PubMed: 10677042]
201. Castrillo A, Pennington DJ, Otto F, Parker PJ, Owen MJ, Bosca L. Protein kinase Cepsilon is required for macrophage activation and defense against bacterial infection. *The Journal of experimental medicine*. 2001; 194:1231–1242. [PubMed: 11696589]
202. Leitges M, Sanz L, Martin P, Duran A, Braun U, Garcia JF, Camacho F, Diaz-Meco MT, Rennert PD, Moscat J. Targeted disruption of the zetaPKC gene results in the impairment of the NF-kappaB pathway. *Molecular cell*. 2001; 8:771–780. [PubMed: 11684013]
203. Martin P, Duran A, Minguet S, Gaspar ML, Diaz-Meco MT, Rennert P, Leitges M, Moscat J. Role of zeta PKC in B-cell signaling and function. *The EMBO journal*. 2002; 21:4049–4057. [PubMed: 12145205]
204. Sharif TR, Sharif M. Overexpression of protein kinase C epsilon in astroglial brain tumor derived cell lines and primary tumor samples. *International journal of oncology*. 1999; 15:237–243. [PubMed: 10402232]
205. Murray NR, Jamieson L, Yu W, Zhang J, Gokmen-Polar Y, Sier D, Anastasiadis P, Gatalica Z, Thompson EA, Fields AP. Protein kinase Cdelta is required for Ras transformation and colon carcinogenesis in vivo. *The Journal of cell biology*. 2004; 164:797–802. [PubMed: 15024028]
206. Stallings-Mann M, Jamieson L, Regala RP, Weems C, Murray NR, Fields AP. A novel small-molecule inhibitor of protein kinase Cdelta blocks transformed growth of non-small-cell lung cancer cells. *Cancer research*. 2006; 66:1767–1774. [PubMed: 16452237]
207. Nanjundan M, Nakayama Y, Cheng KW, Lahad J, Liu J, Lu K, Kuo WL, Smith-McCune K, Fishman D, Gray JW, Mills GB. Amplification of MDS1/EVI1 and EVI1, located in the 3q26.2 amplicon, is associated with favorable patient prognosis in ovarian cancer. *Cancer research*. 2007; 67:3074–3084. [PubMed: 17409414]
208. Liu Y, Su W, Thompson EA, Leitges M, Murray NR, Fields AP. Protein kinase Cbeta2 regulates its own expression in rat intestinal epithelial cells and the colonic epithelium in vivo. *The Journal of biological chemistry*. 2004; 279:45556–45563. [PubMed: 15322124]
209. Sledge GW Jr, Gokmen-Polar Y. Protein kinase C-beta as a therapeutic target in breast cancer. *Seminars in oncology*. 2006; 33:S15–18. [PubMed: 16797377]

210. Mochly-Rosen D, Das K, Grimes KV. Protein kinase C, an elusive therapeutic target? Nature reviews. Drug discovery. 2012; 11:937–957.
211. Iwamoto T, Hagiwara M, Hidaka H, Isomura T, Kioussis D, Nakashima I. Accelerated proliferation and interleukin-2 production of thymocytes by stimulation of soluble anti-CD3 monoclonal antibody in transgenic mice carrying a rabbit protein kinase C alpha. The Journal of biological chemistry. 1992; 267:18644–18648. [PubMed: 1382058]
212. Konopatskaya O, Poole AW. Protein kinase Calpha: disease regulator and therapeutic target. Trends in pharmacological sciences. 2010; 31:8–14. [PubMed: 19969380]
213. Nasir O, Wang K, Foller M, Gu S, Bhandaru M, Ackermann TF, Boini KM, Mack A, Klingel K, Amato R, Perrotti N, Kuhl D, Behrens J, Stournaras C, Lang F. Relative resistance of SGK1 knockout mice against chemical carcinogenesis. IUBMB life. 2009; 61:768–776. [PubMed: 19548318]
214. Kobayashi T, Deak M, Morrice N, Cohen P. Characterization of the structure and regulation of two novel isoforms of serum- and glucocorticoid-induced protein kinase. The Biochemical journal. 1999; 344(Pt 1):189–197. [PubMed: 10548550]
215. Lang F, Bohmer C, Palmada M, Seebohm G, Strutz-Seebohm N, Vallon V. (Patho)physiological significance of the serum- and glucocorticoid-inducible kinase isoforms. Physiological reviews. 2006; 86:1151–1178. [PubMed: 17015487]
216. Wulff P, Vallon V, Huang DY, Volkl H, Yu F, Richter K, Jansen M, Schlunz M, Klingel K, Loffing J, Kauselmann G, Bosl MR, Lang F, Kuhl D. Impaired renal Na(+) retention in the sgk1-knockout mouse. The Journal of clinical investigation. 2002; 110:1263–1268. [PubMed: 12417564]
217. Grahammer F, Artunc F, Sandulache D, Rexhepaj R, Friedrich B, Risler T, McCormick JA, Dawson K, Wang J, Pearce D, Wulff P, Kuhl D, Lang F. Renal function of gene-targeted mice lacking both SGK1 and SGK3. American journal of physiology. Regulatory, integrative and comparative physiology. 2006; 290:R945–950.
218. Wang K, Gu S, Nasir O, Foller M, Ackermann TF, Klingel K, Kandolf R, Kuhl D, Stournaras C, Lang F. SGK1-dependent intestinal tumor growth in APC-deficient mice. Cellular physiology and biochemistry: international journal of experimental cellular physiology, biochemistry, and pharmacology. 2010; 25:271–278.
219. Towhid ST, Liu GL, Ackermann TF, Beier N, Scholz W, Fuchss T, Toulany M, Rodemann HP, Lang F. Inhibition of colonic tumor growth by the selective SGK inhibitor EMD638683. Cellular physiology and biochemistry: international journal of experimental cellular physiology, biochemistry, and pharmacology. 2013; 32:838–848.
220. Bruhn MA, Pearson RB, Hannan RD, Sheppard KE. Second AKT: the rise of SGK in cancer signalling. Growth factors. 2010; 28:394–408. [PubMed: 20919962]
221. Vasudevan KM, Barbie DA, Davies MA, Rabinovsky R, McNear CJ, Kim JJ, Hennessy BT, Tseng H, Pochanard P, Kim SY, Dunn IF, Schinzel AC, Sandy P, Hoersch S, Sheng Q, Gupta PB, Boehm JS, Reiling JH, Silver S, Lu Y, Stemke-Hale K, Dutta B, Joy C, Sahin AA, Gonzalez-Angulo AM, Lluch A, Rameh LE, Jacks T, Root DE, Lander ES, Mills GB, Hahn WC, Sellers WR, Garraway LA. AKT-independent signaling downstream of oncogenic PIK3CA mutations in human cancer. Cancer cell. 2009; 16:21–32. [PubMed: 19573809]
222. Szmulewitz RZ, Chung E, Al-Ahmadie H, Daniel S, Kocherginsky M, Razmaria A, Zagaja GP, Brendler CB, Stadler WM, Conzen SD. Serum/glucocorticoid-regulated kinase 1 expression in primary human prostate cancers. The Prostate. 2012; 72:157–164. [PubMed: 21563193]
223. Abbruzzese C, Mattarocci S, Pizzuti L, Mileo AM, Visca P, Antoniani B, Alessandrini G, Facciolo F, Amato R, D'Antona L, Rinaldi M, Felsani A, Perrotti N, Paggi MG. Determination of SGK1 mRNA in non-small cell lung cancer samples underlines high expression in squamous cell carcinomas. Journal of experimental & clinical cancer research: CR. 2012; 31:4. [PubMed: 22240294]
224. Chu S, Rushdi S, Zumpe ET, Mamers P, Healy DL, Jobling T, Burger HG, Fuller PJ. FSH-regulated gene expression profiles in ovarian tumours and normal ovaries. Molecular human reproduction. 2002; 8:426–433. [PubMed: 11994539]

225. Chung EJ, Sung YK, Farooq M, Kim Y, Im S, Tak WY, Hwang YJ, Kim YI, Han HS, Kim JC, Kim MK. Gene expression profile analysis in human hepatocellular carcinoma by cDNA microarray. *Molecules and cells*. 2002; 14:382–387. [PubMed: 12521301]
226. Hutchinson JN, Jin J, Cardiff RD, Woodgett JR, Muller WJ. Activation of Akt-1 (PKB-alpha) can accelerate ErbB-2-mediated mammary tumorigenesis but suppresses tumor invasion. *Cancer research*. 2004; 64:3171–3178. [PubMed: 15126356]
227. Kim JK, Fillmore JJ, Sunshine MJ, Albrecht B, Higashimori T, Kim DW, Liu ZX, Soos TJ, Cline GW, O'Brien WR, Littman DR, Shulman GI. PKC-theta knockout mice are protected from fat-induced insulin resistance. *The Journal of clinical investigation*. 2004; 114:823–827. [PubMed: 15372106]
228. Sun Z, Arendt CW, Ellmeier W, Schaeffer EM, Sunshine MJ, Gandhi L, Annes J, Petrzilka D, Kupfer A, Schwartzberg PL, Littman DR. PKC-theta is required for TCR-induced NF-kappaB activation in mature but not immature T lymphocytes. *Nature*. 2000; 404:402–407. [PubMed: 10746729]
229. Yang Q, Guan KL. Expanding mTOR signaling. *Cell research*. 2007; 17:666–681. [PubMed: 17680028]
230. Klemptner SJ, Myers AP, Cantley LC. What a tangled web we weave: emerging resistance mechanisms to inhibition of the phosphoinositide 3-kinase pathway. *Cancer discovery*. 2013; 3:1345–1354. [PubMed: 24265156]
231. Shaw RJ, Cantley LC. Ras, PI(3)K and mTOR signalling controls tumour cell growth. *Nature*. 2006; 441:424–430. [PubMed: 16724053]
232. Cantley LC. The phosphoinositide 3-kinase pathway. *Science*. 2002; 296:1655–1657. [PubMed: 12040186]
233. Yuan TL, Cantley LC. PI3K pathway alterations in cancer: variations on a theme. *Oncogene*. 2008; 27:5497–5510. [PubMed: 18794884]
234. Song MS, Salmena L, Pandolfi PP. The functions and regulation of the PTEN tumour suppressor. *Nature reviews. Molecular cell biology*. 2012; 13:283–296.
235. Long X, Lin Y, Ortiz-Vega S, Yonezawa K, Avruch J. Rheb binds and regulates the mTOR kinase. *Current biology: CB*. 2005; 15:702–713. [PubMed: 15854902]
236. Sun Y, Fang Y, Yoon MS, Zhang C, Rocco M, Zwartkruis FJ, Armstrong M, Brown HA, Chen J. Phospholipase D1 is an effector of Rheb in the mTOR pathway. *Proceedings of the National Academy of Sciences of the United States of America*. 2008; 105:8286–8291. [PubMed: 18550814]
237. Toschi A, Lee E, Xu L, Garcia A, Gadir N, Foster DA. Regulation of mTORC1 and mTORC2 complex assembly by phosphatidic acid: competition with rapamycin. *Molecular and cellular biology*. 2009; 29:1411–1420. [PubMed: 19114562]
238. Shaw RJ, Kosmatka M, Bardeesy N, Hurley RL, Witters LA, DePinho RA, Cantley LC. The tumor suppressor LKB1 kinase directly activates AMP-activated kinase and regulates apoptosis in response to energy stress. *Proceedings of the National Academy of Sciences of the United States of America*. 2004; 101:3329–3335. [PubMed: 14985505]
239. Hasumi Y, Baba M, Ajima R, Hasumi H, Valera VA, Klein ME, Haines DC, Merino MJ, Hong SB, Yamaguchi TP, Schmidt LS, Linehan WM. Homozygous loss of BHD causes early embryonic lethality and kidney tumor development with activation of mTORC1 and mTORC2. *Proceedings of the National Academy of Sciences of the United States of America*. 2009; 106:18722–18727. [PubMed: 19850877]
240. Dennis MD, Coleman CS, Berg A, Jefferson LS, Kimball SR. REDD1 enhances protein phosphatase 2A-mediated dephosphorylation of Akt to repress mTORC1 signaling. *Science signaling*. 2014; 7:ra68. [PubMed: 25056877]
241. Luo J, Manning BD, Cantley LC. Targeting the PI3K-Akt pathway in human cancer: rationale and promise. *Cancer cell*. 2003; 4:257–262. [PubMed: 14585353]
242. Harrison DE, Strong R, Sharp ZD, Nelson JF, Astle CM, Flurkey K, Nadon NL, Wilkinson JE, Frenkel K, Carter CS, Pahor M, Javors MA, Fernandez E, Miller RA. Rapamycin fed late in life extends lifespan in genetically heterogeneous mice. *Nature*. 2009; 460:392–395. [PubMed: 19587680]

243. Neff F, Flores-Dominguez D, Ryan DP, Horsch M, Schroder S, Adler T, Afonso LC, Aguilar-Pimentel JA, Becker L, Garrett L, Hans W, Hettich MM, Holtmeier R, Holter SM, Moreth K, Pohn C, Puk O, Racz I, Rathkolb B, Rozman J, Naton B, Ordemann R, Adamski J, Beckers J, Bekeredjian R, Busch DH, Ehninger G, Graw J, Hofler H, Klingenspor M, Klopstock T, Ollert M, Stypmann J, Wolf E, Wurst W, Zimmer A, Fuchs H, Gailus-Durner V, Hrabe de Angelis M, Ehninger D. Rapamycin extends murine lifespan but has limited effects on aging. *The Journal of clinical investigation*. 2013; 123:3272–3291. [PubMed: 23863708]
244. Phung TL, Ziv K, Dabydeen D, Eyiah-Mensah G, Riveros M, Perruzzi C, Sun J, Monahan-Earley RA, Shiojima I, Nagy JA, Lin MI, Walsh K, Dvorak AM, Briscoe DM, Neeman M, Sessa WC, Dvorak HF, Benjamin LE. Pathological angiogenesis is induced by sustained Akt signaling and inhibited by rapamycin. *Cancer cell*. 2006; 10:159–170. [PubMed: 16904613]
245. Sarbassov DD, Ali SM, Sengupta S, Sheen JH, Hsu PP, Bagley AF, Markhard AL, Sabatini DM. Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB. *Molecular cell*. 2006; 22:159–168. [PubMed: 16603397]
246. Motzer RJ, Escudier B, Oudard S, Hutson TE, Porta C, Bracarda S, Grunwald V, Thompson JA, Figlin RA, Hollaender N, Urbanowitz G, Berg WJ, Kay A, Lebwohl D, Ravaud A, Group R-S. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. *Lancet*. 2008; 372:449–456. [PubMed: 18653228]
247. Blagosklonny MV. TOR-centric view on insulin resistance and diabetic complications: perspective for endocrinologists and gerontologists. *Cell death & disease*. 2013; 4:e964. [PubMed: 24336084]
248. Ingels A, Zhao H, Thong AE, Saar M, Valta MP, Nolley R, Santos J, Peehl DM. Preclinical trial of a new dual mTOR inhibitor, MLN0128, using renal cell carcinoma tumorgrafts. *International journal of cancer. Journal international du cancer*. 2014; 134:2322–2329. [PubMed: 24243565]
249. Chresta CM, Davies BR, Hickson I, Harding T, Cosulich S, Critchlow SE, Vincent JP, Ellston R, Jones D, Sini P, James D, Howard Z, Dudley P, Hughes G, Smith L, Maguire S, Hummersone M, Malagu K, Menear K, Jenkins R, Jacobsen M, Smith GC, Guichard S, Pass M. AZD8055 is a potent, selective, and orally bioavailable ATP-competitive mammalian target of rapamycin kinase inhibitor with in vitro and in vivo antitumor activity. *Cancer research*. 2010; 70:288–298. [PubMed: 20028854]
250. Pike KG, Malagu K, Hummersone MG, Menear KA, Duggan HM, Gomez S, Martin NM, Ruston L, Pass SL, Pass M. Optimization of potent and selective dual mTORC1 and mTORC2 inhibitors: the discovery of AZD8055 and AZD2014. *Bioorganic & medicinal chemistry letters*. 2013; 23:1212–1216. [PubMed: 23375793]
251. Zaytseva YY, Valentino JD, Gulhati P, Evers BM. mTOR inhibitors in cancer therapy. *Cancer letters*. 2012; 319:1–7. [PubMed: 22261336]
252. Heckl D, Kowalczyk MS, Yudovich D, Belizaire R, Puram RV, McConkey ME, Thielke A, Aster JC, Regev A, Ebert BL. Generation of mouse models of myeloid malignancy with combinatorial genetic lesions using CRISPR-Cas9 genome editing. *Nature biotechnology*. 2014; 32:941–946.
253. Kwong LN, Costello JC, Liu H, Jiang S, Helms TL, Langsdorf AE, Jakubosky D, Genovese G, Muller FL, Jeong JH, Bender RP, Chu GC, Flaherty KT, Wargo JA, Collins JJ, Chin L. Oncogenic NRAS signaling differentially regulates survival and proliferation in melanoma. *Nature medicine*. 2012; 18:1503–1510.

Highlights

- mTOR pathway component-related engineered mouse models are summarized.
- Pathological alterations for discussed mTOR pathway components are outlined.
- An oncogenic or tumor suppressor role is assigned for mTOR pathway components.
- Further perspectives for generating additional mouse models are provided.

Figure 1.

A schematic illustration of the mTOR signaling pathway, including major upstream regulators and downstream substrates for both the mTORC2 and mTORC1 kinase complexes. The major mTORC1 upstream regulators include Rheb, TSC1/2, AMPK, Rag and Akt. When activated at the lysosome membrane, mTORC1 directly phosphorylates 4E-BP1, S6K, SREBP and certain autophagy components, which exert their functions to modulate protein synthesis, lipid and lysosome biosynthesis, energy metabolism and autophagy. On the other hand, relatively little is known about the upstream regulators of mTORC2, although it is well established that mTORC2 is sensitive to growth factors. The downstream targets of mTORC2 are AGC family of kinases, including Akt, SGK and PKC, which regulate the cytoskeleton polarization and cell survival /metabolism. The mTOR pathway components with established mouse models are marked in bold. Oncogenic proteins in this pathway are labeled in red color, while tumor suppressors are labeled in green.

Figure 2.

A schematic illustration of various tissue-specific knockout mouse models for the indicated critical mTOR signaling components. Please note that certain cell type-specific knockout mouse models are not included in this figure.

Figure 3.

A summary of future perspectives to determine the physiological roles for additional members of the mTOR oncogenic pathway in tumorigenesis.

Table 1

Mouse phenotypes upon knockout of the various core subunits of mTORC complex.

mTOR complex subunits	Mouse models	Major phenotypes	References
mTOR	<i>mTOR^{-/-}</i>	Embryonic lethal around E5.5–6.5; blastocysts fail to expansion	[35]
	<i>mTOR^{+/-}</i>	Without overt defects	[36]
	<i>mTOR^{H/H}</i>	Longer lifespan	[37]
	<i>Conditional mTOR^{-/-} (muscle)</i>	Severe myopathy	[38]
mLST8	<i>mLST8^{-/-}</i>	Embryonic lethal around E10.5; vascular development defects	[18]
Raptor	<i>Raptor^{-/-}</i>	Embryonic death before E7, blastocysts fail to expand	[18]
	<i>Conditional Raptor^{-/-} (skeletal muscle)</i>	Severe muscle dystrophy	[40]
	<i>Conditional Raptor^{-/-} (heart)</i>	Dilated cardiomyopathy 6 weeks post-deletion	[41]
	<i>Conditional Raptor^{-/-} (liver)</i>	40% smaller liver mass	[43]
	<i>Conditional Raptor^{-/-} (brain)</i>	Smaller brain beginning at E17.5; die shortly after birth	[42]
	<i>Conditional Raptor^{-/-} (HSC)</i>	Impairments in granulocytes and B cells development	[44]
	<i>Conditional Raptor^{-/-} (AML mouse model)</i>	Significantly inhibited leukemia progression	[44]
Rictor	<i>Rictor^{-/-}</i>	Embryonic lethal at E10.5–11.5; vascular development defects	[18, 45]
	<i>Rictor^{+/-}Pten^{+/-}</i>	Less prostate tumor incidence; less severe lesions and longer lifespan than <i>Pten^{+/-}</i> mice	[52]
	<i>Conditional Rictor^{-/-}(muscle)</i>	Local glucose metabolism disorder	[46]
	<i>Conditional Rictor^{-/-}(neuron)</i>	Smaller brain and body size; schizophrenic-like behavior	[49, 50]
	<i>Conditional Rictor^{-/-}(liver)</i>	Abnormal response to insulin	[47]
	<i>Conditional Rictor^{-/-}(fat cell)</i>	Whole body glucose and lipid metabolism disorders	[48]
Sin1	<i>Sin1^{-/-}</i>	Embryonic lethal at E10.5~15.5; cardiovascular development defects	[53]
	<i>Conditional Sin1^{-/-} (B cell)</i>	Increased V(D)J recombinase activity	[53]
	<i>Conditional Sin1^{-/-} (T cell)</i>	Increased thymic T-regulatory cells	[54]

Keys: +, wild type allele; -, null allele; H, hypomorphic allele.

Table 2

Major physiological functions of the mTORC1 upstream regulator.

mTORC1 upstream regulators	Mouse models		Major phenotypes	Putative roles in tumorigenesis	References
	Knockout (KO)	Transgenic (Tg)			
TSC1	<i>Tsc1^{-/-}</i>		Embryonic lethal at E10.5–11.5	Tumor suppressor	[65, 108]
	<i>Tsc1^{+/-}</i>		Developed renal tumors and liver hemangiomas at the age of 15–18 months		[67, 108]
	<i>Conditional Tsc1^{-/-} (prostate epithelium)</i>		Developed prostatic intraepithelial neoplasia (mPIN) at 6 months stage		[68]
	<i>Conditional Tsc1^{-/-} (liver)</i>		Developed sporadic hepatocellular carcinoma		[69]
	<i>Conditional Tsc1^{-/-} (mammary tissue)</i>		Significantly promoted breast cancer cell growth <i>in vivo</i>		[70]
	<i>Conditional Tsc1^{-/-} Pten^{-/-} (liver)</i>		Exhibited accelerated tumor development and greater tumor numbers		[71]
	<i>Conditional Tsc1^{-/-} (skeletal muscle)</i>		Developed a late-onset myopathy marked with autophagic substrates accumulation		[109]
	<i>Conditional Tsc1^{-/-} (bone marrow)</i>		Showed developmental block of iNKT differentiation		[110]
	<i>Conditional Tsc1^{-/-} (cardiovascular system)</i>		Severe hypertrophy in both ventricles		[111]
	<i>Conditional Tsc1^{-/-} (hypothalamus)</i>		Developed obesity		[112]
TSC2	<i>Conditional Tsc1^{-/-} (glia)</i>		Exhibited progressive epilepsy and premature death		[113]
	<i>Tsc2^{-/-}</i>		Embryonic lethal at E9.5–12.5	Tumor suppressor	[66, 114]
	<i>Tsc2^{+/-}</i>		Develops spontaneous tumors in renal, liver and lung at the age of 15 months		[66, 114]
	<i>Tsc2^{+/-} Pten^{+/-}</i>		Showed spontaneous prostate cancer		[73]
	<i>Conditional Tsc2^{-/-} (uterine)</i>		Developed uterine tumor		[72]
	<i>Conditional Tsc2^{-/-} (neuron)</i>		Showed reduced survival rates and enlarged brain and cortical neuron		[115]
	<i>Conditional Tsc2^{-/-} (glia)</i>		Exhibited epilepsy, premature death		[115]
Rheb	<i>Rheb^{-/-}</i>		Embryonic lethal around mid-gestation	Emerging role as an oncogene	[79]
	<i>Rheb1^{-/-}</i>		Embryonic lethal at E10.5–E11.5 stage		[80]
	<i>Rheb2^{-/-}</i>		Without obvious abnormal until adulthood		[80]

mTORC1 upstream regulators	Mouse models		Major phenotypes	Putative roles in tumorigenesis	References
	Knockout (KO)	Transgenic (Tg)			
Rag	<i>Conditional Rheb1^{-/-} (neural progenitor cell)</i>		Impairment of brain postnatal myelination		[80]
	<i>Conditional Rheb2^{-/-} (liver)</i>		Showed a 2-fold increase of mitochondrial proteins		[81]
		<i>Rheb transgenic lymphoma mice</i>	Promoted lymphoma progression and drug-resistant		[82]
		<i>Rheb transgenic (Pten^{+/-} mice)</i>	Exhibited accelerated prostate cancer progression compared to <i>Pten^{+/-}</i> mice		[83]
	<i>RagA^{-/-}</i>		Embryonic death at E10.5; loss of mTORC1 activity and severe growth defects	<i>To be determined</i>	[89]
	<i>RagB^{-/-}</i>		No overt phenotypes		[89]
	<i>RagA^{-/-}/RagB^{-/-}</i>		Embryonic lethal at E10.5; more robust loss of mTORC1 activity		[89]
	<i>Conditional RagA^{-/-} (heart)</i>		No overt phenotypes		[90]
	<i>Conditional RagB^{-/-} (heart)</i>		No overt phenotypes		[90]
	<i>Conditional RagA^{-/-}/RagB^{-/-} (heart)</i>		Cardiac hypertrophy; defects in autophagy; phenocopies lysosome storage diseases		[90]
	<i>Conditional RagA^{-/-}/RagB^{-/-} (liver)</i>		More robust loss of mTORC1 activity comparing with <i>RagA^{-/-}</i> mice		[89]
AMPK		<i>RagA Knock-in mice</i>	Glucose homeostasis defects; autophagy defects; died before postnatal day 1	<i>Context-dependent</i>	[88]
	<i>Ampkα1^{-/-}</i>		Showed increased bone remodeling; decreased fertility function		[100, 116]
	<i>Ampkα2^{-/-}</i>		Dysfunctional glucose metabolism and more likely to development obesity under high-fat diet		[99]
	<i>Ampkβ1^{-/-}</i>		Reduced food intake and protection against diet-induced obesity		[117]
	<i>Ampkβ2^{-/-}</i>		Reduced exercise capacity and promote diet-induced obesity		[118]
	<i>Ampkγ3^{-/-}</i>		Impaired glycogen re-synthesis after exercise		[101]
	<i>Ampkα1^{-/-}/Ampkα2^{-/-}</i>		Embryonic lethal at E10.5 stage		[97]
	<i>Conditional Ampkα1^{-/-}/Ampkα2^{-/-} (muscle)</i>		Showed larger size of myofibers and a higher mass in the biopsy muscle		[98]

mTORC1 upstream regulators	Mouse models		Major phenotypes	Putative roles in tumorigenesis	References
	Knockout (KO)	Transgenic (Tg)			
	<i>Conditional Ampkβ1^{-/-} /Ampkβ2^{-/-} (muscle)</i>		Physical inactive; reduced mitochondrial content in muscle cells		[102, 119]
	<i>Conditional Ampka1^{-/-} (Eμ-Myc induced lymphoma)</i>		Showed acceleration of <i>Myc</i> -induced lymphomagenesis		[105]

Keys: +, wild type allele; −, null allele.

Table 3

Major physiological functions of the mTORC1 substrates.

mTORC1 downstream effectors	Mouse models		Major phenotypes	Putative roles in tumorigenesis	References
	Knockout	Transgenic			
4E-BP1	<i>4E-bp1^{-/-}</i>		Smaller white fat pads; impaired granulocytic early differentiation	<i>Emerging role as a tumor suppressor</i>	[125, 127]
	<i>4E-bp1^{-/-}/4E-bp2^{-/-}</i>		Increased insulin resistance		[126]
	<i>4E-bp1^{-/-}/4E-bp2^{-/-}/p53^{-/-}</i>		Increased tumor-free survival		[129]
		<i>Transgenic 4E-BP1</i>	Inhibited tumor growth <i>in vivo</i>		[130]
S6K	<i>S6k1^{-/-}</i>		Smaller body size; obesity-like metabolism disorder	<i>To be determined</i>	[133–136]
	<i>S6k2^{-/-}</i>		Slightly larger body size		[134]
	<i>S6k1^{-/-}/S6k2^{-/-}</i>		Sharp reduction in viability		[134]
	<i>Srebp1^{-/-}</i>		Embryonic lethal at E11		[140]
SREBP	<i>Srebp1c^{-/-}</i>		Lipid metabolism disorder in liver	<i>Emerging role as an oncogene</i>	[146, 160]
	<i>Srebp2^{-/-}</i>		Embryonic lethal at E7–E8		[160]
		<i>Truncated Srebp-1a transgenic (liver)</i>	Developed a massive fatty liver enriched with cholesterol and triglycerides		[147]
		<i>Truncated Srebp-1c transgenic (liver)</i>	Developed a fatty liver enriched with triglycerides		[148]
		<i>Truncated Srebp-2 transgenic (liver)</i>	Developed a fatty liver enriched with cholesterol		[145]
ULK1	<i>Ulk1^{-/-}</i>		Defects in reticulocyte maturation	<i>To be determined</i>	[157]
Transcription factor EB (TFEB)	<i>Tfeb^{-/-}</i>		Embryonic lethal between E9.5–10.5	<i>To be determined</i>	[156]
	<i>Conditional Tfeb^{-/-} (osteoclast)</i>		Increased bone mass		[161]
Bcln1	<i>Bcln1^{+/-}</i>		Increased spontaneous malignancy	<i>Tumor suppressor</i>	[158]

Keys: +, wild type allele; -, null allele.

Table 4

Major physiological functions of the mTORC2 substrates.

mTORC2 substrates	Mouse models		Major phenotypes	Putative roles in tumorigenesis	References
	knockout	Transgenic			
Akt	<i>Akt1</i> ^{-/-}		Reduced body, brain and liver size	Oncogene	[173, 176]
	<i>Akt2</i> ^{-/-}		Insulin resistance and diabetes		[174, 177]
	<i>Akt3</i> ^{-/-}		Reduction in body size and brain weight		[175, 178]
	<i>Akt1</i> ^{-/-} / <i>Akt2</i> ^{-/-}		Born with reduced body size; died shortly after birth		[180]
	<i>Akt1</i> ^{-/-} / <i>Akt3</i> ^{-/-}		Embryonic lethal at E11-E12		[179]
	<i>Akt2</i> ^{-/-} / <i>Akt3</i> ^{-/-}		Reduced body size; insulin resistance		[181]
	<i>Conditional Akt1</i> ^{-/-} (mammary gland)		Inhibited tumor initiation; accelerated tumor invasion		[189]
	<i>Conditional Akt2</i> ^{-/-} (mammary gland)		Accelerated tumor initiation; inhibited tumor invasion		[189]
		<i>Akt1 transgenic</i> (ErbB-2 transgenic mammary gland mice)	Promoted tumor development; inhibited metastasis		[226]
		<i>Akt2 transgenic</i> (ErbB-2 transgenic mammary gland mice)	Inhibited tumor development; promoted metastasis		[226]
PKC	<i>Pkc-α</i> ^{-/-}		Diminished glucose induced albuminuria	Isoform-specific (<i>Pkc-ε</i> and <i>Pkc-η</i> are oncogenes)	[194]
	<i>Pkc-β</i> ^{-/-}		Humoral immunodeficiency; resistance to carcinogen-induced colonic tumors		[195, 208]
	<i>Pkc-γ</i> ^{-/-}		Mild deficits in spatial and contextual learning		[196, 197]
	<i>Pkc-δ</i> ^{-/-}		B-cell dysfunction		[198, 199]
	<i>Pkc-ε</i> ^{-/-}		Severely impaired innate immunity; decreased hyperalgesia		[200, 201]
	<i>Pkc-ζ</i> ^{-/-}		B cell malfunction		[202, 203]
	<i>Pkc-θ</i> ^{-/-}		Impaired cell activation; protective from fat-induced insulin resistance		[227, 228]
		<i>Transgenic Pkc-βII</i> (<i>pkc-β</i> ^{-/-})	Restored the susceptibility to carcinogen - induced colon tumor		[208]

mTORC2 substrates	Mouse models		Major phenotypes	Putative roles in tumorigenesis	References
	knockout	Transgenic			
SGK		<i>Transgenic Pkc-ι</i>	Susceptible to carcinogen-induced colon carcinogenesis		[205]
	<i>Sgk1^{-/-}</i>		Impaired renal sodium retention under low salt diet	<i>Context-dependent</i>	[216]
	<i>Sgk3^{-/-}</i>		Delayed hair growth		[217]
	<i>Sgk1^{-/-}/Sgk3^{-/-}</i>		Delayed hair growth; lower blood pressure		[217]
	<i>Compound Sgk1^{-/-}/Apc^{Mm^{+/+}} mice</i>		Inhibited tumorigenesis		[218]

Keys: +, wild type allele; −, null allele; H, hypomorphic allele; AOM, azoxymethane.